神奈川県立がんセンター臨床研究所
お問い合わせ

がん分子病態学部

当研究所について
研究活動
基礎的技術支援コアセンター
共同研究したい
学生として研究したい
研究員として働きたい
情報セキュリティポリシー
公的研究費の適正管理
交通案内
お問い合わせ
病院サイトはこちら

がん分子病態学部について

がん分子病態学部では、がんセンター臨床各科と多数の共同研究を進めると共に、「がん組織における低酸素、脂質欠乏環境を標的とした新規の早期診断マーカー・治療分子標的の開発」、「がん関連血栓塞栓症（CAT）の早期予測マーカー・治療分子標的の探索」、「がん周囲微小環境の多面的理解による、転移進行がんに対する新規がん治療法の開発」、「形態情報・エピゲノム情報のAI解析から作出する新規診断・治療効果予測・予後判定ツールの開発」の4つの研究課題を遂行しています。また、質の高い臨床研究基盤の構築と、それを用いた研究、特に個別化医療の開発研究を促進するために、がんセンター生体試料センターにおける臓器横断的な患者試料バンキングに於いて中心的役割を果たし、また、患者由来異種移植片（Patient Derived Xenograft; PDX）モデルの作製をがん治療学部と共同して進めています。PDXモデルは、希少がんとして、当センターの骨軟部腫瘍と、県立こども医療センターとの連携のもと、小児がんの肺転移巣を移植の対象としています。

研究課題

がん組織における低酸素、脂質欠乏環境を標的とした研究

　がん組織における低酸素、脂質欠乏環境を標的とした研究では、低酸素と共に欠乏する栄養因子との相加、相乗効果でがん細胞に発現が誘導される遺伝子群CD69、ICAM-1、血液凝固第7因子FVII、組織因子TFに焦点を絞って研究を進めています。特に今年度は、卵巣明細胞癌細胞におけるICAM-1依存性アポトーシス抑制機構、特にフィラグリンの役割の解明、さらには明細胞型腎細胞癌にて高発現するICAM-1についてその発現メカニズムに関する研究を遂行しました。現在まで、動物実験によりフィラグリンの腫瘍進展への効果を確認しています。また明細胞型腎細胞癌におけるICAM-1発現は卵巣明細胞癌細胞同様にHIF2a依存的であることなどが明らかにするなどの成果を挙げました。今後の機能解析等を経てICAM-1―フィラグリン経路の治療標的化の可能性を検討予定です。

がん関連血栓塞栓症（CAT）に関する研究

　がん関連血栓塞栓症（CAT）に関する研究では、組織因子の抗原量と凝固活性を膵臓癌患者の血液検体について経時的に測定し、CAT発症患者は発症直前に凝固活性が上昇することを明らかにしました。今後の詳細な研究によりCAT発症メカニズム解明、より正確なCAT発症予測モデルの開発を目指していきます。また、アメロイドコンストリクターを用いて免疫不全マウスの下大静脈を狭窄させることによりCAT研究に有用な新規静脈血栓形成モデルを構築しました。

転移進行がんに対する新規がん治療法の開発研究

　転移進行がんに対する新規がん治療法の開発研究では、引き続き腫瘍微小環境に存在する脂肪細胞・脂肪分泌因子の意義について研究を進めました。前年度に確認した骨転移巣の病理組織学的解析・遺伝子発現解析により明らかにした骨髄脂肪細胞の腫瘍免疫抑制作用、腫瘍関連線維芽細胞誘導促進作用、薬剤抵抗性促進作用について論文に纏め発表しました。また、本研究をin vivoで進めるための選択的骨転移マウスモデルを開発し特許出願を行ないました(特願2024-008814)。がんと脂肪の相互作用研究成果の臨床応用を進めるため、がんと脂肪の相互作用を顕著に認めるがん種（卵巣がん、大腸がん、肉腫）のPDXモデル作製を進め、卵巣がん、大腸がんで安定的なPDX株の樹立に成功しました。さらに本年度は細胞実験、動物実験により、脂肪細胞分泌因子である脂肪分泌因子（アディポカイン）の機能を検討し、がんの増殖・アポトーシスを直接制御するアディポカインを見出しました。現在動物実験によりアディポカインシグナルによる腫瘍増殖制御機構を解析中です。先年度に脂肪前駆細胞からの分化誘導法を作製した特定のアディポカインを分泌する脂肪細胞と合わせて、がん・脂肪相互作用を明らかにし、アディポカインによる転移進行がんの新規治療法開発を目指します。

形態情報・エピゲノム情報のAI解析を基盤とする診断・治療効果予測・予後判定ツールの開発研究

　形態情報・エピゲノム情報のAI解析を基盤とする診断・治療効果予測・予後判定ツールの開発研究では、形態情報のAI解析を行うデジタルデバイスの開発に注力しています。形態解析の際基本となる、ヘマトキシリンエオジン染色標本において着目した病変部と同一座標上の病変を、複数の免疫染色標本においてAI解析により自動的に認識するシステムを開発しました。本システムにより、病理診断における免疫染色の染色性評価が客観的に、精確に行えることが可能になります。本研究成果は職務発明検討会議にて職務発明と認定され、特許出願を行いました。今後、本デジタルデバイスを用いて、AI解析を用いた形態情報の診断・治療への応用の準備、および研究面におけるがん・間質細胞相互作用の形態学的解析への活用を、共同研究を通してさらに進める予定です。

研究論文

2023年

  1. Sato S. Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers. Cell Commun Signal.; 22(1):52, 2024 (Published 2024 Jan 18) IF=8.4
  2. Natsume K, Ye J, Mukai Y, Yamakawa K, Tanimoto M, Ito H, Miyagi Y, Daigo Y, Muto-Ishizuka M, Kadota K, Haba R, Suizu F. Discrepancies Between Morphological and Immunohistochemical Classifications Are Associated With Prognoses and Subtypes of Lung Cancer. Anticancer Res 44(2):711-722, 2024. (Published 2024 Feb) IF=2.0
  3. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Morita J, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Clinical Significance of Tryptophanyl-tRNA Synthetase 1 Gene Expression in Patients With Locally Advanced Gastric Cancer. Anticancer Res 44(2):673-678, 2024. (Published 2024 Feb) IF=2.0
  4. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Asialoglycoprotein Receptor 2 Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection. Anticancer Res 44(1):397-402, 2024. (Published 2024 Jan) IF=2.0
  5. Kuwatuka Y, Kasajima R, Yamaguchi R, Uchida N, Konuma T, Tanaka M, Shingai N, Miyakoshi S, Kozai Y, Uehara Y, Eto T, Toyosaki M, Nishida T, Ishimaru F, Kato K, Fukuda T, Imoto S, Atsuta Y, Takahashi S. Mahine Learning Prediction Model for Neutrophil Recovery after Unrelated Cord Blood Transplantation. Transplantation and Cellular Therapy. (In publication. 2024 Feb.) Kuwatuka Y and Kasajima R are the first equal contribution. IF=3.2
  6. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Morita J, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Clinical Significance of Pregnancy Zone Protein Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection. Anticancer Res 44(1):369-374, 2024. (Published 2024 Jan) IF=2.0
  7. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Clinical Significance of Chitinase-3-like Protein 1 Gene Expression in Patients With Locally Advanced Gastric Cancer. Anticancer Res 44(1):307-312. (Published 2024 Jan) IF=2.0
  8. Okubo Y, Sato S, Terao H, Yamamoto Y, Suzuki A, Hasegawa C, Yoshioka E, Ono K, Washimi K, Yokose T, Nakaigawa N, Kishida T, Miyagi Y. Review of the Developing Landscape of Prostate Biopsy and Its Roles in Prostate Cancer Diagnosis and Treatment. Arch Esp Urol 76(9):633-642, 2023. (Published 2023 Nov) IF=0.38
  9. Isaka T, Miyagi Y, Yokose T, Saito H, Kasajima R, Watabe K, Shigeta N, Kikunishi N, Shigefuku S, Murakami K, Adachi H, Nagashima T, Ito H. Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1-N2 epidermal growth factor receptor mutant lung adenocarcinoma. Transl Lung Cancer Res 12(10):2001-2014, 2023 (Published 2023 Oct 31)　IF＝2
  10. Li M, Nishimura T, Takeuchi Y, Hongu T, Wang Y, Shiokawa D, Wang K, Hirose H, Sasahara A, Yano M, Ishikawa S, Inokuchi M, Ota T, Tanabe M, Tada KI, Akiyama T, Cheng X, Liu CC, Yamashita T, Sugano S, Uchida Y, Chiba T, Asahara H, Nakagawa M, Sato S, Miyagi Y, Shimamura T, Nagai LAE, Kanai A, Katoh M, Nomura S, Nakato R, Suzuki Y, Tojo A, Voon DC, Ogawa S, Okamoto K, Foukakis T, Gotoh N. FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters. J Clin Invest 133(22):e166666, 2023 (Published 2023 Nov 15)　IF=15.9
  11. Takeuchi K, Tabe S, Takahashi K, Aoshima K, Matsuo M, Ueno Y, Furukawa Y, Yamaguchi K, Ohtsuka M, Morinaga S, Miyagi Y, Yamaguchi T, Tanimizu N, Taniguchi H. Incorporation of human iPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts. Cell Rep.;42(11):113420, 2023 (Published 2023 Nov 12) IF=8.8
  12. Saito Y, Nakamura S, Watanabe K, Ikegami H, Shinmura N, Sato S, Miyagi Y, Narimatsu H. Age group differences in psychological distress and leisure-time exercise/socioeconomic status during the COVID-19 pandemic: a cross-sectional analysis during 2020 to 2021 of a cohort study in Japan. Front Public Health 11:1233942, 2023 (Published 2023 Oct 25)　IF=3.3
  13. Shiraishi K, Takahashi A, Momozawa Y, Daigo Y, Kaneko S, Kawaguchi T, Kunitoh H, Matsumoto S, Horinouchi H, Goto A, Honda T, Shimizu K, Torasawa M, Takayanagi D, Saito M, Saito A, Ohe Y, Watanabe SI, Goto K, Tsuboi M, Tsuchihara K, Takata S, Aoi T, Takano A, Kobayashi M, Miyagi Y, Tanaka K, Suzuki H, Maeda D, Yamaura T, Matsuda M, Shimada Y, Mizuno T, Sakamoto H, Yoshida T, Goto Y, Yoshida T, Yamaji T, Sonobe M, Toyooka S, Yoneda K, Masago K, Tanaka F, Hara M, Fuse N, Nishizuka SS, Motoi N, Sawada N, Nishida Y, Kumada K, Takeuchi K, Tanno K, Yatabe Y, Sunami K, Hishida T, Miyazaki Y, Ito H, Amemiya M, Totsuka H, Nakayama H, Yokose T, Ishigaki K, Nagashima T, Ohtaki Y, Imai K, Takasawa K, Minamiya Y, Kobayashi K, Okubo K, Wakai K, Shimizu A, Yamamoto M, Iwasaki M, Matsuda K, Inazawa J, Shiraishi Y, Nishikawa H, Murakami Y, Kubo M, Matsuda F, Kamatani Y, Hamamoto R, Matsuo K, Kohno T. Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses. Cancer Commun (Lond) 44(2): 287-293, 2024 (Published 2024 Feb) IF=16.2
  14. Mezawa Y, Wang T, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Yang L, Maruyama R, Seimiya H, Orimo A. Glutamine deficiency drives transforming growth factor-β signaling activation that gives rise to myofibroblastic carcinoma-associated fibroblasts. Cancer Sci 114(11):4376-4387, 2023 (Published 2023 Nov)　IF＝7
  15. Goto H, Ohtsu T, Ito M, Sagisaka M, Naruto T, Nagai JI, Kitagawa N, Tanaka M, Yanagimachi M, Hiroshima Y, Miyagi Y. A short-term three dimensional culture-based drug sensitivity test is feasible for malignant bone tumors. Hum Cell 36(6):2152-2161, 2023 (Published 2023 Nov)　IF=4.3
  16. Sato S, Nakagawa M, Terashima T, Morinaga S, Miyagi Y, Yoshida E, Yoshimura T, Seiki M, Kaneko S, Ueno M, Yamashita T, Koshikawa N. EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma. Cancer Res Commun 3(9):1862-1874, 2023. (Published 2023 Sep 15)　IF=11.2
  17. Hiratsuka T, Ito S, Sakai R, Yokose T, Endo T, Daigo Y, Miyagi Y, Tsuruyama T. Proteome analysis of CD5-positive diffuse large B cell lymphoma FFPE tissue reveals downregulation of DDX3X, DNAJB1, and B cell receptor signaling pathway proteins including BTK and Immunoglobulins. Clin Proteomics 20(1):36, 2023 (Published 2023 Sep 13) IF=3.8
  18. Suzuki M, Kasajima R, Yokose T, Shimizu E, Hatakeyama S, Yamaguchi K, Yokoyama K, Katayama K, Yamaguchi R, Furukawa Y, Miyano S, Imoto S, Shinozaki-Ushiku A, Ushiku T, Miyagi Y. KMT2C expression and DNA homologous recombination repair factors in lung cancers with a high-grade fetal adenocarcinoma component. Transl Lung Cancer Res 12(8):1738-1751, 2023 (Published 2023 Aug 30) IF=4.0
  19. Suzuki MM, Iijima K, Ogami K, Shinjo K, Murofushi Y, Xie J, Wang X, Kitano Y, Mamiya A, Kibe Y, Nishimura T, Ohka F, Saito R, Sato S, Kobayashi J, Yao R, Miyata K, Kataoka K, Suzuki HI, Kondo Y. TUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation. Nat Commun.;14(1):4521, 2023 (Published 2023 Aug 22)　IF=16.6
  20. Kawachi K, Tang X, Kasajima R, Yamanaka T, Shimizu E, Katayama K, Yamaguchi R, Yokoyama K, Yamaguchi K, Furukawa Y, Miyano S, Imoto S, Yoshioka E, Washimi K, Okubo Y, Sato S, Yokose T, Miyagi Y. Genetic analysis of low-grade adenosquamous carcinoma of the breast progressing to high-grade metaplastic carcinoma. Breast Cancer Res Treat 202(3):563-573, 2023 (Published 2023 Dec)　IF=3.8
  21. Koyama Y, Okazaki H, Shi Y, Mezawa Y, Wang Z, Sakimoto M, Ishizuka A, Ito Y, Koyama T, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Sugahara K, Hino O, Yang L, Maruyama R, Katakura A, Yasukawa T, Orimo A. Increased RUNX3 expression mediates tumor-promoting ability of human breast cancer-associated fibroblasts. Cancer Med 12(17):18062-18077, 2023. (Published 2023 Sep) IF=4.0
  22. Okubo Y, Toda S, Sato S, Yoshioka E, Ono K, Hasegawa C, Washimi K, Yokose T, Miyagi Y, Iwasaki H, Hayashi H. Histological findings of thyroid cancer after lenvatinib therapy. Histopathology 83(4):657-663, 2023. (Published 2023 Oct)　IF=6.4
  23. Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, Kouro T, Igarashi Y, Tokito T, Kato T, Kondo T, Murakami S, Usui R, Himuro H, Horaguchi S, Tsuji K, Murotani K, Ban T, Tamura T, Miyagi Y, Sasada T. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures. J Immunother Cancer 11(7):e006788, 2023. (Published 2023 July) IF=10.9
  24. Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, Hung RJ, Chen K, Shu XO, 52 authors, Miyagi Y, 158 authors, Kohno T, Lan Q. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. Nat Commun 14(1):3043, 2023. (Published 2023 May 26)　IF=16.6
  25. Washimi K, Kasajima R, Shimizu E, Sato S, Okubo Y, Yoshioka E, Narimatsu H, Hiruma T, Katayama K, Yamaguchi R, Yamaguchi K, Furukawa Y, Miyano S, Imoto S, Yokose T, Miyagi Y. Histological markers, sickle-shaped blood vessels, myxoid area, and infiltrating growth pattern help stratify the prognosis of patients with myxofibrosarcoma/undifferentiated sarcoma. Sci Rep 13(1):6744, 2023. (Published 2023 Apr 25)　IF=5.0

2022年

  1. Sato S, Hiruma T, Koizumi M, Yoshihara M, Nakamura Y, Tadokoro H, Motomatsu S, Yamanaka T, Washimi K, Okubo Y, Yoshioka E, Kasajima R, Yamashita T, Kishida T, Yokose T, and Miyagi Y. Bone marrow adipocytes induce cancer-associated fibroblasts and immune evasion, enhancing invasion and drug resistance. Cancer Sci. In press. (2023 Mar)
  2. Koizume S, Kanayama T, Kimura Y, Hirano H, Takahashi T, Ota Y, Miyazaki K, Yoshihara M, Nakamura Y, Yokose T, Kato H, Takenaka K, Sato S, Tadokoro H, Miyagi E, Miyagi Y. Cancer cell-derived CD69 induced under lipid and oxygen starvation promotes ovarian cancer progression via fibronectin. Cancer Sci. Online ahead of print (2023 Feb)
  3. Okubo Y, Sato S, Hasegawa C, Koizumi M, Suzuki T, Yamamoto Y, Yoshioka E, Ono K, Washimi K, Yokose T, Kishida T, Miyagi Y. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores. Hum Pathol. Online ahead of print (2023 Feb )
  4. Matsuda Y, Ye J, Yamakawa K, Mukai Y, Azuma K, Wu L, Masutomi K, Yamashita T, Daigo Y, Miyagi Y, Yokose T, Oshima T, Ito H, Morinaga S, Kishida T, Minamoto T, Kojima M, Kaneko S, Haba R, Kontani K, Kanaji N, Okano K, Muto-Ishizuka M, Yokohira M, Saoo K, Imaida K, Suizu F. Association of longer telomere length in cancer cells and cancer-associated fibroblasts with worth prognosis. J Natl Cancer Inst 115(2):208-218, 2023. (Published 2023 Feb)
  5. Nagai K, Asano R, Sekiguchi F, Asai-Sato M, Miyagi Y, Miyagi E. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 228(2):207.e1-207.e9, 2023. (Published 2023 Feb)
  6. Wang X, Xiang H, Toyoshima Y, Shen W, Shichi S, Nakamoto H, Kimura S, Sugiyama K, Homma S, Miyagi Y, Taketomi A, Kitamura H. Arginase-1 inhibition reduces migration ability and metastatic colonization of colon cancer cells. Cancer Metab 11(1):1, 2023. (Published 2023 Jan)
  7. Hasegawa C, Washimi K, Hiroshima Y, Kasajima R, Kikuchi K, Notomi T, Kato H, Hiruma T, Sato S, Okubo Y, Yoshioka E, Ono K, Miyagi Y, Yokose T. Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genomic profiling. Diagn Pathol 18(1):5, 2023 (Published 2023 Jan)
  8. Natsume H, Szczepaniak K, Yamada H, Iwashita Y, Gędek M, Šuto J, Ishino K, Kasajima R, Matsuda T, Manirakiza F, Nzitakera A, Wu Y, Xiao N, He Q, Guo W, Cai Z, Ohta T, Szekely T, Kadar Z, Sekiyama A, Oshima T, Yoshikawa T, Tsuburaya A, Kurono N, Wang Y, Miyagi Y, Gurzu S, Sugimura H. Non-CpG sites preference in G:C > A:T transition of TP53 in gastric cancer of Eastern Europe (Poland, Romania and Hungary) compared to East Asian countries (China and Japan). Genes Environ 45(1):1, 2023. (Published 2023 Jan)
  9. Suematsu H, Sakamaki K, Oue N, Hiroshima Y, Kimura Y, Onuma S, Hashimoto I, Nagasawa S, Aoyama T, Yamada T, Tamagawa H, Ogata T, Rino Y, Masuda M, Yasui W, Miyagi Y, Oshima T. Clinical Significance of SEC11A Expression in Patients With Locally Advanced Gastric Cancer. Anticancer Res 42(12):5885-5890, 2022. (Published 2022 Dec)
  10. Koizumi M, Sato S, Yoshihara M, Nakamura Y, Terao H, Okubo Y, Washimi K, Yoshioka E, Yokose T, Kishida T, Koshikawa N, Miyagi Y. Chronological Change in EPHA2 Protein Expression Is Associated With Recurrence of Bladder Cancer. Anticancer Res 42(12):5783-5794, 2022. (Published 2022 Dec)
  11. Ota Y, Sato S, Yoshihara M, Nakamura Y, Miyagi E, Miyagi Y. A practical spatial analysis method for elucidating the biological mechanisms of cancers with abdominal dissemination in vivo. Sci Rep 12(1):20303, 2022. (Published 2022 Nov)
  12. Okubo Y, Yamamoto Y, Terao H, Suzuki T, Koizumi M, Yoshioka E, Washimi K, Sato S, Yokose T, Kishida T, Miyagi Y. Significance of non-standardized magnetic resonance imaging abnormalities and subsequent targeted prostate cancer biopsy for pathologists: A retrospective observational study. Pathol Res Pract 240:154188. (Published 2022 Dec)
  13. Hashimoto I, Kimura Y, Oue N, Hiroshima Y, Aoyama T, Rino Y, Yokose T, Yasui W, Miyagi Y, Oshima T. Identification of a Biomarker Combination for Survival Stratification in pStage II/III Gastric Cancer after Curative Resection. Cancers 14(18):4427, 2022. (Published 2022 Sep)
  14. Ikeda S, Kato T, Kenmotsu H, Ogura T, Sato Y, Hino A, Harada T, Kubota K, Tokito T, Okamoto I, Furuya N, Yokoyama T, Hosokawa S, Iwasawa T, Kasajima R, Miyagi Y, Misumi T, Okamoto H. Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study. Oncologist 27(9):720-e702, 2022. (Published 2022 Sep)
  15. Shintaro Kazama, Kazuaki Yokoyama, Toshimitsu Ueki, Hiroko Kazumoto, Hidetoshi Satomi, Masahiko Sumi, Ichiro Ito, Nozomi Yusa, Rika Kasajima, Eigo Shimizu, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Arinobu Tojo, Hikaru Kobayashi. Case report: Common Clonal Origin of Concurrent Langerhans Cell Histiocytosis and Acute Myeloid Leukemia. Front Oncol 12:974307, 2022. (Published 2022 Sep)
  16. Ozaki A, Motomura H, Tamori S, Onaga C, Nagashima Y, Kotori M, Matsuda C, Matsuda A, Mochizuki N, Sato T, Hara Y, Sato K, Miyagi Y, Nagashima Y, Hanawa T, Harada Y, Xiong Y, Sasaki K, Ohno S, Akimoto K. High Expression of p62 and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer. Anticancer Res 42(7):3299-3312, 2022. (Published 2022 July)
  17. Suematsu H, Hashimoto I, Hiroshima Y, Watanabe H, Kano K, Takahashi K, Aoyama T, Yamada T, Tamagawa H, Ogata T, Yukawa N, Rino Y, Masuda M, Miyagi Y, Oshima T. Clinical Significance of EREG Gene Expression in Gastric Cancer Tissue After Curative Surgery. Anticancer Res 42(8):3873-3878, 2022. (Published 2022 Aug)
  18. Oshima T, Tsuburaya A, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Tan P, Grabsch HI, Sakamoto J, Tanaka S. Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial. Sci Rep 12(1):8509, 2022. (Published 2022 May)
  19. Azuma K, Xiang H, Tagami T, Kasajima R, Kato Y, Karakawa S, Kikuchi S, Imaizumi A, Matsuo N, Ishii H, Tokito T, Kawahara A, Murotani K, Sasada T, Miyagi Y, Hoshino T. Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model. J Immunother Cancer 10(5):e004420, 2022. (Published 2022 May)
  20. Koizume S, Takahashi T, Nakamura Y, Yoshihara M, Ohta Y, Sato S, Tadokoro H, Yokose T, Kato H, Miyagi E, Miyagi Y. Lipophagy-ICAM-1 pathway associated with fatty acid and oxygen deficiencies is involved in poor prognoses of ovarian clear cell carcinoma. British J Cancer 127(3):462-473, 2022. (Published 2022 Aug)
  21. Koizume S, Kobayashi S, Ruf W, Miyagi Y. Authors' reply to the Letter to the Editor: Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Cancer Sci 113(5):1888-1890, 2022. (Published 2022 May)
  22. Suzuki K, Igata H, Abe M, Yamamoto Y; small RNA based cancer classification project (Miyagi Y, Sato S and others). Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. Cancer Sci 113(6):2144-2166, 2022. (Published 2022 Jun)
  23. Matsuda Y, Yamashita T, Ye J, Yasukawa M, Yamakawa K, Mukai Y, Machitani M, Daigo Y, Miyagi Y, Yokose T, Oshima T, Ito H, Morinaga S, Kishida T, Minamoto T, Yamada S, Takei J, Kaneko MK, Kojima M, Kaneko S, Masaki T, Hirata M, Haba R, Kontani K, Kanaji N, Miyatake N, Okano K, Kato Y, Masutomi K. Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs. J Pathol 257(2):172-185, 2022. (Published 2022 Jun)
  24. Okubo Y, Yamamoto Y, Sato S, Yoshioka E, Suzuki M, Washimi K, Osaka K, Suzuki T, Yokose T, Kishida T, Miyagi Y. Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution. Virchows Arch 480(5):979-987, 2022. (published 2022 May)
  25. Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan AL, Hoppe MM, Jeyasekharan AD, Ng CCY, De Simone M, Grabsch HI, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut 71(4):676-685, 2022. (published 2022 April)

2021年

  1. Suzuki K, Igata H, Abe M, Yamamoto Y, small RNA based cancer classification project (including Miyagi Y, Sato S and 24 Kanagawa Cancer Center doctors of multiple departments as authors). Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. Cancer Sci (2022 Feb 14, in press)
  2. Takeda R, Yokoyama K, Fukuyama T, Kawamata T, Ito M, Yusa N, Kasajima R, Shimizu E, Ohno N, Uchimaru K, Yamaguchi R, Imoto S, Miyano S, Tojo A. Repeated lineage switches in an elderly case of refractory B-cell acute lymphoblastic leukemia with MLL gene amplification: A case report and literature review. Front Oncol (2022 Feb, in press)  
  3. Matsuda Y, Yamashita T, Ye J, Yasukawa M, Yamakawa K, Mukai Y, Machitani M, Daigo Y, Miyagi Y, Yokose T, Oshima T, Ito H, Morinaga S, Kishida T, Minamoto T, Yamada S, Takei J, Kaneko MK, Kojima M, Kaneko S, Masaki T, Hirata M, Haba R, Kontani K, Kanaji N, Miyatake N, Okano K, Kato Y, Masutomi K. Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs. J Pathol. (2022 Jan 30, Online ahead of print)
  4. Okubo Y, Yamamoto Y, Sato S, Yoshioka E, Suzuki M, Washimi K, Osaka K, Suzuki T, Yokose T, Kishida T, Miyagi Y. Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution. Virchows Arch. (2022 Jan 11, Online ahead of print)
  5. Sugiyama K, Washimi K, Sato S, Hiruma T, Sakai M, Okubo Y, Miyagi Y, Yokose T. Differential diagnosis of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma by cytological analysis. Diagn Cytopathol. (2022 Jan 4, Online ahead of print)
  6. Hishida A, Yamada H, Ando Y, Okugawa Y, Shiozawa M, Miyagi Y, Daigo Y, Toiyama Y, Shirai Y, Tanaka K, Kubo Y, Okada R, Nagayoshi M, Tamura T, Mori A, Kondo T, Hamajima N, Takeuchi K, Wakai K. Investigation of miRNA expression profiles using cohort samples reveals potential early detectability of colorectal cancers by serum miR-26a-5p before clinical diagnosis. Oncol Lett 23(3):87, 2022. 2022 Mar
  7. Ida A, Okubo Y, Kasajima R, Washimi K, Sato S, Yoshioka E, Osaka K, Suzuki T, Yamamoto Y, Yokose T, Kishida T, Miyagi Y. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies. Pathol Res Pract 229:153731. 2022 Jan
  8. Yada E, Kasajima R, Niida A, Imoto S, Miyano S, Miyagi Y, Sasada T, Wada S. Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer. Biomedicines 9(10):1396, 2021. 2021 Oct　
  9. Hoshino D, Kato H, Fukumura K, Mayeda A, Miyagi Y, Seiki M, Koshikawa N. A novel LAMC2 fusion protein has tumor promoting properties in ovarian carcinoma. Cancer Sci 112(12):4957-4967, 2021. 2021 Dec
  10. Sueyoshi K, Komura D, Katoh H, Yamamoto A, Onoyama T, Chijiwa T, Isagawa T, Tanaka M, Suemizu H, Nakamura M, Miyagi Y, Aburatani H, Ishikawa S. Multi-tumor analysis of cancer-stroma interactomes of patient-derived xenografts unveils the unique homeostatic process in renal cell carcinomas. iScience 24(11):103322, 2021. 2021 Oct　
  11. Segami K, Aoyama T, Hiroshima Y, Komori K, Hashimoto I, Watanabe H, Kano K, Nagasawa S, Nakazono M, Maezawa Y, Fujikawa H, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Siozawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Miyagi Y, Saeki H, Oshima T. Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer. In Vivo 35(5):2771-2777, 2021. 2021 Sep-Oct　
  12. Kobayashi S, Koizume S, Takahashi T, Ueno M, Oishi R, Nagashima S, Sano Y, Fukushima T, Tezuka S, Morimoto M, Nakamura S, Narimatsu H, Ruf W, Miyagi Y. Tissue Factor and its Procoagulant Activity on Cancer-Associated Thromboembolism in Pancreatic Cancer. Cancer Sci 112(11):4676-4691, 2021. 2021 Nov　
  13. Hiroshima K, Wu D, Koh E, Sekine Y, Ozaki D, Yusa T, Nakazawa T, Tsuji S, Miyagi Y, Walts AE, Marchevsky AM, Husain AN, Imai K. Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas. Pathol Int 71(9):604-613, 2021. 2021 Sep
  14. Hatori S, Sakamaki K, Yokohori T, Kimura Y, Hiroshima Y, Hashimoto I, Komori K, Watanabe H, Kano K, Fujikawa H, Aoyama T, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Shiozawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Saeki H, Miyagi Y, Oshima T. Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1. Anticancer Res 41(7):3583-3588, 2021. 2021 July　
  15. Tang X, Nakanishi Y, Kobayashi H, Nishimaki H, Kusumi Y, Miyagi Y, Masuda S. Mixed ductal-lobular carcinoma: an analysis of CDH1 DNA copy number variation and mutation. Breast Cancer 28(6):1318-1327, 2021. 2021 Nov　
  16. Motomura H, Ozaki A, Tamori S, Onaga C, Nozaki Y, Waki Y, Takasawa R, Yoshizawa K, Mano Y, Sato T, Sasaki K, Ishiguro H, Miyagi Y, Nagashima Y, Yamamoto K, Sato K, Hanawa T, Tanuma SI, Ohno S, Akimoto K. Glyoxalase 1 and protein kinase Cλ as potential therapeutic targets for late-stage breast cancer. Oncol Lett 22(1):547, 2021. 2021 July 　
  17. Ono K, Kasajima R, Katayama K, Miyagi Y, Yokose T. Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin. Pathol Int 71(8):491-499, 2021. 2021 Aug　
  18. Miyagi E, Arakawa N, Sakamaki K, Yokota NR, Yamanaka T, Yamada Y, Yamaguchi S, Nagao S, Hirashima Y, Kasamatsu Y, Kato H, Mogami T, Miyagi Y, Kobayashi H. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary. Miyagi E, Arakawa N, Sakamaki K, Yokota NR, Yamanaka T, Yamada Y, Yamaguchi S, Nagao S, Hirashima Y, Kasamatsu Y, Kato H, Mogami T, Miyagi Y, Kobayashi H. Int J Clin Oncol 26(7):1336-1344, 2021. 2021 July          
  19. Yamaguchi K, Kasajima R, Takane K, Hatakeyama S, Shimizu E, Yamaguchi R, Katayama K, Arai M, Ishioka C, Iwama T, Kaneko S, Matsubara N, Moriya Y, Nomizu T, Sugano K, Tamura K, Tomita N, Yoshida T, Sugihara K, Nakamura Y, Miyano S, Furukawa Y, Ikenoue T. Application of targeted nanopore sequencing for the screening and determination of structural variants in patients with Lynch syndrome. J Hum Genet 66:1053–1060, 2021. 2021 May　
  20. Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan AL, Hoppe MM, Jeyasekharan AD, Ng CCY, De Simone M, Grabsch HI, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut gutjnl-2021-324060, 2021. 2021 May 　
  21. Sato S, Maki S, Yamanaka T, Hoshino D, Ota Y, Yoshioka E, Kawachi K, Washimi K, Suzuki M, Ohkubo Y, Yokose T, Yamashita T, Ohtori S, Miyagi Y. Machine learning-based image analysis for accelerating the diagnosis of complicated preneoplastic and neoplastic ductal lesions in breast biopsy tissues. Breast Cancer Res Treat 188(3):649-659. 2021 Aug 　
  22. Taniguchi H, Natori Y, Miyagi Y, Hayashi K, Nagamura F, Kataoka K, Imai K. Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex. Int J Cancer 149(3):646-656, 2021. 2021 Aug
  23. Suganuma N, Kawachi K, Yamashita T, Yamanaka T, Sugawara Y, Matsubara Y, Yamazaki Y, Kohagura K, Toda S, Okamoto S, Yoshida T, Rino Y, Masuda M, Narimatsu H, Fujita H, Yoshioka E, Yokose T, Furuta K, Miyagi Y. Quality Control of Breast Cancer Surgery Samples - Introducing Time Stamp Checking. Biopreserv Biobank 19(5):369-375, 2021. 2021 Oct　
  24. Watanabe T, Shiozawa M, Kimura Y, Hiroshima Y, Hashimoto I, Komori K, Watanabe H, Kano K, Fujikawa H, Aoyama T, Numata M, Yamada T, Tamagawa H, Ogata T, Yukawa N, Morinaga S, Rino Y, Masuda M, Miyagi Y, Oshima T. Clinical significance of stanniocalcin2 mRNA expression in patients with colorectal cancer. Anticancer Res 41(4):2117-2122, 2021. 2021 April　
  25. Okubo Y, Sato S, Osaka K, Yamamoto Y, Suzuki T, Ida A, Yoshioka E, Suzuki M, Washimi K, Yokose T, Kishida T, Miyagi Y. Clinicopathological Analysis of the ISUP Grade Group And Other Parameters in Prostate Cancer: Elucidation of Mutual Impact of the Various Parameters. Front Oncol 11:695251. 2021 July　
  26. Hiroshima K, Wu D, Hamakawa S, Tsuruoka S, Ozaki D, Orikasa H, Hasegawa M, Koh E, Sekine Y, Yonemori Y, Nabeshima K, Tsuji S, Miyagi Y, Imai K. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion. Diagn Cytopathol 49(5):622-632, 2021. 2021 May　
  27. Toda S, Sato S, Saito S, Sekihara K, Matsui A, Murayama D, Nakayama H, Suganuma N, Okubo Y, Hayashi H, Iwasaki H, Miyagi Y and Hoshino D. TROP-2,Nectin-4,GPNMB, and B7-H3 are potentially therapeutic targets for anaplastic thyroid carcinoma. Cancers, 2022 in press
  28. Nagasawa S, Tsuchida K, Shiozawa M, Hiroshima Y, Kimura Y, Hashimoto I, Watanabe H, Kano K, Numata M, Aoyama T, Sato S, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Morinaga S, Yukawa N, Rino Y, Masuda M, Saeki H, Miyagi Y, Oshima T. Clinical Significance of Chemokine Receptor CXCR4 and CCR7 mRNA Expression in Patients With Colorectal Cancer. Anticancer Res. 2021 Sep;41(9):4489-4495. doi: 10.21873/anticanres.15259. PMID: 34475074.

過年度

  1. Suzuki M, Kasajima R, Yokose T, Ito H, Shimizu E, Hatakeyama S, Yokoyama K, Yamaguchi R, Furukawa Y, Miyano S, Imoto S, Yoshioka E, Washimi K, Okubo Y, Kawachi K, Sato S, Miyagi Y. Comprehensive molecular analysis of genomic profiles and PD-L1 expression in high-grade fetal lung adenocaricinoma. Transl Lung Cancer Res 10(3):1292-1304, 2021. (published Mar 2021)
  2. Isaka T, Yokose T, Ito H, Nakayama H, Miyagi Y, Saito H, Masuda M. Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR. BMC Pulm Med 21(1):100, 2021. (published 23 Mar 2021)
  3. Ota Y, Koizume S, Nakamura Y, Yoshihara M, Takahashi T, Sato, S, Myoba S, Ohtake N, Kato H, Yokose T, Miyagi E, Miyagi Y. Tissue factor pathway inhibitor-2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix. Oncol Rep 45(3), 1023-1032, 2021. (published Mar 2021)
  4. kubo Y, Nukada S, Shibata Y, Osaka K, Yoshioka E, Suzuki M, Washimi K, Kawachi K, Kishida T, Yokose T, Miyagi Y. Primary solitary fibrous tumour of the prostate: A case report and literature review. Malays J Pathol 42(3):449-453, 2020.
  5. Yamada A, Suzuki C, Shima H, Kida K, Adachi S, Yamamoto S, Narui K, Tanabe M, Shimizu D, Taniguchi R, Oshi M, Takabe K, Miyagi Y, Ichikawa Y, Ishikawa T, Endo I. Aldehyde Dehydrogenase 1-related Genes in Triple-negative Breast Cancer Investigated Using Network Analysis. Anticancer Res 40(12):6733-6742, 2020. doi: 10.21873/anticanres.14696.
  6. Nagashima T, Oshima T, Hiroshima Y, Yokose T, Woo T, Rino Y, Masuda M, Miyagi Y, Ito H, Nakayama H.Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer. Anticancer Res 40(11):6407-6416, 2020. doi: 10.21873/anticanres.14662.
  7. Onozawa H, Saito H, Sunami K, Kubo T, Yamamoto N, Kasajima R, Ohtsu T, Hiroshima Y, Kanamori H, Yokose T, Miyagi Y. Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib. Thorac Cancer 11(12):3599-3604, 2020. doi: 10.1111/1759-7714.13694.
  8. Hashimoto I, Oue N, Kimura Y, Hiroshima Y, Hara K, Maezawa Y, Kano K, Fujikawa H, Aoyama T, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Shiozawa M, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T.Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery. Anticancer Res 40(10):5815-5821, 2020. doi:10.21873/anticanres.14599.
  9. Miyazaki K, Togo S, Okamoto R, Idiris A, Kumagai H, Miyagi Y. Collective cancer cell invasion in contact with fibroblasts through integrin-ﾎｱ5ﾎｲ1/fibronectin interaction in collagen matrix. Cancer Sci 111(12):4381-4392, 2020. doi: 10.1111/cas.14664.
  10. Muguruma M, Teraoka S, Miyahara K, Ueda A, Asaoka M, Okazaki M, Kawate T, Kuroda M, Miyagi Y, Ishikawa T. Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines. Biochem Biophys Res Commun. Biochem Biophys Res Commun 533(3):268-274, 2020. doi: 10.1016/j.bbrc.2020.08.075.
  11. Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Yokose T, Hiroshima Y, Aoyama T, Hayashi T, Ogata T, Cho H, Rino Y, Masuda M, Tsuburaya A, Sakamoto J. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget 11(30):2906-2918, 2020. doi: 10.18632/oncotarget.27658.
  12. Yoshida T, Suganuma N, Sato S, Toda S, Nakayama H, Masudo K, Okubo Y, Hayashi H, Yokose T, Koshikawa N, Rino Y, Iwasaki H, Miyagi Y, Masuda M, Hoshino D. Membrane type 1 matrix metalloproteinase regulates anaplastic thyroid carcinoma cell growth and invasion into the collagen matrix. Biochem Biophys Res Commun 529(4):1195-1200, 2020. doi: 10.1016/j.bbrc.2020.06.043.
  13. Meier A, Nekolla K, Hewitt LC, Earle S, Yoshikawa T, Oshima T, Miyagi Y, Huss R, Schmidt G, Grabsch HI. Hypothesis-free deep survival learning applied to the tumour microenvironment in gastric cancer. J Pathol Clin Res 6(4):273-282, 2020. doi: 10.1002/cjp2.170.
  14. Manabe S, Kasajima R, Murakami S, Miyagi Y, Yokose T, Kondo T, Saito H, Ito H, Kaneko T, Yamada K. Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique. Thorac Cancer 11(8):2262-2269, 2020. doi: 10.1111/1759-7714.13536.
  15. Katayama K, Ishikawa D, Miyagi Y, Takemiya S, Okamoto N, Ogawa A. Qualitative analysis of cancer telephone consultations: Differences in the counseling needs of Japanese men and women. Patient Educ Couns S0738-3991(20)30278-0, 2020. doi: 10.1016/j.pec.2020.05.012.
  16. Nakamura M, Takano A, Thang PM, Tsevegjav B, Zhu M, Yokose T, Yamashita T, Miyagi Y, Daigo Y. Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer. Int J Oncol 51(1): 277-288, 2020. doi: 10.3892/ijo.2020.5060.
  17. Ikeda S, Kato T, Kenmotsu H, Ogura T, Iwasawa S, Iwasawa T, Kasajima R, Miyagi Y, Misumi T, Yamanaka T, Okamoto H. A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study. Ther Adv Med Oncol 12:1758835920922022, 2020. doi: 10.1177/1758835920922022.
  18. Jikuya R, Kishida T, Sakaguchi M, Yokose T, Yasui M, Hashizume A, Tatenuma T, Mizuno N, Muraoka K, Umemoto S, Kawai M, Yoshihara M, Nakamura Y, Miyagi Y, Sasada T. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma. Cancer Immunol Immunother 69(10):2041-2051, 2020. doi: 10.1007/s00262-020-02608-6.
  19. Nakayama H, Kawachi K, Suganuma N, Yoshida T, Yamashita T, Yamanaka T, Matsubara Y, Kohagura K, Toda S, Nakamura Y, Miyagi Y, Rino Y, Masuda M. EZH2 and MMSET Were Identified as Potentially Useful Therapeutic Targets in Metaplastic Breast Carcinoma. Anticancer Res 40(4):2133-2139, 2020. doi: 10.21873/anticanres.14172.
  20. Samanta S, Tamura S, Dubeau L, Mhawech-Fauceglia P, Miyagi Y, Kato H, Lieberman R, Buckanovich RJ, Lin YG, Neamati N. Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma. Sci Rep 10(1):2160, 2020. doi: 10.1038/s41598-020-59116-x.
  21. Hagiwara A, Nakamura Y, Nishimoto R, Ueno S, Miyagi Y. Induction of tryptophan hydroxylase in the liver of subcutaneous tumor model of prostate cancer. Cancer Sci 111(4): 1218-1227, 2020. doi: 10.1111/cas.14333.
  22. Kasajima R, Yamaguchi R, Shimizu E, Tamada Y, Niida A, Tremmel G, Kishida T, Aoki I, Imoto S, Miyano S, Uemura H, Miyagi Y. Variant analysis of prostate cancer in Japanese patients and a new attempt to predict related biological pathways. Oncol Rep 43(3):943-952, 2020. doi: 10.3892/or.2020.7481.
  23. Okamoto N, Mikami H, Nakamura Y, Kusakabe M, Yamamoto N, Takiguchi N, Nabeya Y, Soda H, Fukasawa S, Kishida T, Shiozawa M, Yoshida A, Shimizu T, Fujimoto S, Ueda M, Inagaki S, Miyagi Y, Nagase H. A Nobel Multivariate Index for Cancer Risk Detection Based On the Serum Trace Elements: Metallo-Balance Method. J Cancer Epidemiol Prev (iMedPub) 5(1): 1-9, 2020. (not on PubMed)
  24. Kano K, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Maezawa Y, Aoyama T, Fujikawa H, Hiroshima Y, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Shiozawa M, Yukawa N, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. Impact of the ESM-1 Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 Chemotherapy. In Vivo 34(1):461-467, 2020. doi: 10.21873/invivo.11796.
  25. Endo H, Hama N, Baghdadi M, Ishikawa K, Otsuka R, Wada H, Asano H, Endo D, Konno Y, Kato T, Watari H, Tozawa A, Suzuki N, Yokose T, Takano A, Kato H, Miyagi Y, Daigo Y, Seino KI. Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression. Int Immunol 32(3):175-186, 2020. doi: 10.1093/intimm/dxz074.
  26. Suzuki M, Muroi A, Nojima M, Numata A, Takasaki H, Sakai R, Yokose T, Miyagi Y, Koshikawa N. Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma. Proteomics Clin Appl 14(1): e1900091, 2020. doi: 10.1002/prca.201900091.
  27. Wong JYY, Zhang H, Hsiung CA, Shiraishi K, Yu K, Matsuo K, Wong MP, Hong YC, Wang J, Seow WJ, Wang Z, Song M, Kim HN, Chang IS, Chatterjee N, Hu W, Wu C, Mitsudomi T, Zheng W, Kim JH, Seow A, Caporaso NE, Shin MH, Chung LP, An SJ, Wang P, Yang Y, Zheng H, Yatabe Y, Zhang XC, Kim YT, Cai Q, Yin Z, Kim YC, Bassig BA, Chang J, Ho JCM, Ji BT, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Hosgood HD, Sakamoto H, Kunitoh H, Tsuta K, Watanabe SI, Kubo M, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Shi J, Song L, Hua X, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wei F, Matsuda F, Su J, Kim YH, Oh IJ, Song F, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Chien LH, Xiang YB, Park JY, Kweon SS, Chen CJ, Lee KM, Blechter B, Li H, Gao YT, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Wang WC, Chung CC, Burdett L, Yeager M, Hutchinson A, Berndt SI, Wu W, Pang H, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Zhu M, Chen CH, Yang TY, Xu J, Guan P, Tan W, Wang CL, Hsin M, Sit KY, Ho J, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Lin CC, Park IK, Xu P, Wang Y, He Q, Perng RP, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Li YJ, Li J, Chen H, Yu CJ, Jin L, Chen TY, Jiang SS, Liu J, Yamaji T, Hicks B, Wyatt K, Li SA, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Li X, Ren Y, Cui P, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Chen Y, Yang K, Jiang G, Fei K, Wu G, Lin HC, Chen HL, Fang YH, Tsai FY, Hsieh WS, Yu J, Stevens VL, Laird-Offringa IA, Marconett CN, Rieswijk L, Chao A, Yang PC, Shu XO, Wu T, Wu YL, Lin D, Chen K, Zhou B, Huang YC, Kohno T, Shen H, Chanock SJ, Rothman N, Lan Q. Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics 112(2):1223-1232, 2020. doi: 10.1016/j.ygeno.2019.07.008.
  28. Sawada Y, Kikugawa T, Iio H, Sakakibara I, Yoshida S, Ikedo A, Yanagihara Y, Saeki N, Győrffy B, Kishida T, Okubo Y, Nakamura Y, Miyagi Y, Saika T, Imai Y. GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer. Int J Cancer 146(5):1369-1382, 2020. doi: 10.1002/ijc.32554.
  29. Oneyama M, Sakamoto N, Oue N, Kimura Y, Hiroshima Y, Hashimoto I, Hara K, Maezawa Y, Kano K, Aoyama T, Fujikawa H, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Yukawa N, Shiozawa M, Yoshikawa T, Morinaga S, Rino Y, Masuda M, Miyagi Y, Yasui W, Oshima T. Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy. Anticancer Res 39(12):6567-6573, 2019. doi: 10.21873/anticanres.13872.
  30. Kobayashi T, Baghdadi M, Han N, Murata T, Hama N, Otsuka R, Wada H, Shiozawa M, Yokose T, Miyagi Y, Takano A, Daigo Y, Seino KI. Prognostic value of IL-34 in colorectal cancer patients. Immunol Med 42(4):169-175, 2019. doi: 10.1080/25785826.2019.1691429.
  31. Maezawa Y, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Kano K, Aoyama T, Hiroshima Y, Yamada T, Yamamoto N, Ogata T, Ito H, Cho H, Shiozawa M, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1. J Cancer Res Clin Oncol 146(1):75-86, 2019. doi: 10.1007/s00432-019-03087-8.
  32. Hiroshima Y, Kasajima R, Kimura Y, Komura D, Ishikawa S, Ichikawa Y, Bouvet M, Yamamoto N, Oshima T, Morinaga S, Singh SR, Hoffman RM, Endo I, Miyagi Y. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Cancer Lett 469:217-227, 2019. doi: 10.1016/j.canlet.2019.10.031.
  33. Yoshikawa T, Aoyama T, Sakamaki K, Oshima T, Lin J, Zhang S, Sapari NS, Soong R, Tan I, Chan XB, Bottomley D, Hewitt LC, Arai T, Teh BT, Epstein D, Ogata T, Kameda Y, Miyagi Y, Tsuburaya A, Morita S, Grabsch HI, Tan P. Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. J Cancer 10(21):5130-5138, 2019. doi: 10.7150/jca.34741.
  34. Hashimoto I, Sakamaki K, Oue N, Kimura Y, Hiroshima Y, Hara K, Maezawa Y, Kano K, Aoyama T, Yamada T, Yamamoto N, Ogata T, Ito H, Shiozawa M, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. Clinical significance of PRKCI gene expression in cancerous tissue in patients with gastric cancer. Anticancer Res 39(10): 5715-5720, 2019.
  35. Matsumura Y, Ito Y, Mezawa Y, Sulidan K, Daigo Y, Hiraga T, Mogushi K, Wali N, Suzuki H, Itoh T, Miyagi Y, Yokose T, Shimizu S, Takano A, Terao Y, Saeki H, Ozawa M, Abe M, Takeda S, Okumura K, Habu S, Hino O, Takeda K, Hamada M, Orimo A. Stromal fibroblasts induce metastatic tumor cell clusters via epithelial-mesenchymal plasticity. Life Sci Alliance 2(4), 2019. pii: e201900425. doi: 10.26508/lsa.201900425.
  36. Mezawa Y, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Morimoto C, Hino O, Orimo A. CD26 expression is attenuated by TGF-β and SDF-1 autocrine signaling on stromal myofibroblasts in human breast cancers. Cancer Med 8(8): 3936-3948, 2019
  37. Koizume S, Takahashi T, Yoshihara M, Nakamura Y, Ruf W, Takenaka K, Miyagi E, Miyagi Y. Cholesterol Starvation and Hypoxia Activate the FVII Gene via the SREBP1-GILZ Pathway in Ovarian Cancer Cells to Produce Procoagulant Microvesicles. Thromb Haemost 119(7):1058-1071, 2019
  38. Mochizuki M, Nakamura M, Sibuya R, Okazaki T, Abe J, Nakagawa T, Takahashi S, Yamazaki T, Imai T, Takano A, Ito H, Yokose T, Miyagi Y, Daigo Y, Sato I, Satoh K, Sugamura K, Yamaguchi K, Tamai K. CD271 is a negative prognostic factor and essential for cell proliferation in lung squamous cell carcinoma. Lab Invest 99(9):1349-1362, 2019
  39. Odaka M, Kim H, Nakamura Y, Hattori A, Matsuura K, Iwamura M, Miyagi Y, Yasuda K. Size Distribution Analysis with On-Chip Multi-Imaging Cell Sorter for Unlabeled Identification of Circulating Tumor Cells in Blood. Micromachines (Basel) 25;10(2), 2019. pii: E154. doi: 10.3390/mi10020154.
  40. Murakawa M, Aoyama T, Miyagi Y, Kobayashi S, Ueno M, Morimoto M, Numata M, Yamamoto N, Tamagawa H, Yukawa N, Rino Y, Masuda M, Morinaga S. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. J Cancer 10(3):627-33, 2019. doi: 10.7150/jca.28660.
  41. Miyazaki K, Oyanagi J, Hoshino D, Togo S, Kumagai H, Miyagi Y. Cancer cell migration on elongate protrusions of fibroblasts in collagen matrix. Sci Rep 9(1):292, 2019. doi: 10.1038/s41598-018-36646-z.
  42. Asano R, Asai-Sato M, Matsukuma S, Mizushima T, Taguri M, Yoshihara M, Inada M, Fukui A, Suzuki Y, Miyagi Y, Miyagi E. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities. Fertil Steril 111(1): 178-85, 2018. pii: S0015-0282(18)32073-9. doi: 10.1016/j.fertnstert.2018.09.014
  43. Tezuka S, Ueno M, Kobayashi S, Morimoto M, Ohkawa S, Hirotani A, Tozuka Y, Moriya S, Nakamura Y, Miyagi Y, Sugimori M, Maeda S. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer. Am J Cancer Res 8(10):2096-2105, 2018.
  44. Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K, Wada S, Miyagi Y, Kishida T, Sasada T. Oncotarget. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. Oncotarget 9(75):34066-34078, 2018. doi: 10.18632/oncotarget.26122. eCollection 2018 Sep 25.
  45. Nishikawa K, Tsuburaya A, Yoshikawa T, Kobayashi M, Kawada J, Fukushima R, Matsui T, Tanabe K, Yamaguchi K, Yoshino S, Takahashi M, Hirabayashi N, Sato S, Nemoto H, Rino Y, Nakajima J, Aoyama T, Miyagi Y, Oriuchi N, Yamaguchi K, Miyashita Y, Morita S, Sakamoto J. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). Eur J Cancer 101:220-228, 2018. doi: 10.1016/j.ejca.2018.06.026. Epub 2018 Aug 7.
  46. Aoyama T, Hutchins G, Arai T, Sakamaki K, Miyagi Y, Tsuburaya A, Ogata T, Oshima T, Earle S, Yoshikawa T, Grabsch HI. Identification of a high-risk subtype of intestinal-type Japanese gastric cancer by quantitative measurement of the luminal tumor proportion. Cancer Med. 2018 Aug 29. doi: 10.1002/cam4.1744. [Epub ahead of print]
  47. Suzuki M, Nakatani Y, Ito H, Narimatsu H, Yamada K, Yoshioka E, Washimi K, Okubo Y, Kawachi K, Miyagi Y, Yokose T.Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma. Mod Pathol 31(9):1404-1417, 2018. doi: 10.1038/s41379-018-0057-z.
  48. Shima H, Kida K, Adachi S, Yamada A, Sugae S, Narui K, Miyagi Y, Nishi M, Ryo A, Murata S, Taniguchi H, Ichikawa Y, Ishikawa T, Endo I. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness. Breast Cancer Res Treat 170(3):507-516, 2018. doi: 10.1007/s10549-018-4793-z.
  49. Sumi T, Hirai S, Yamaguchi M, Tanaka Y, Tada M, Yamada G, Hasegawa T, Miyagi Y, Niki T, Watanabe A, Takahashi H, Sakuma Y. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas. Int J Oncol 53(1):33-46, 2018. doi: 10.3892/ijo.2018.4365.
  50. Ogasawara N, Kudo T, Sato M, Kawasaki Y, Yonezawa S, Takahashi S, Miyagi Y, Natori Y, Sugiyama A. Reduction of Membrane Protein CRIM1 Decreases E-Cadherin and Increases Claudin-1 and MMPs, Enhancing the Migration and Invasion of Renal Carcinoma Cells. Biol Pharm Bull 41(4):604-611, 2018. doi: 10.1248/bpb.b17-00990.
  51. Kanai Y, Nishihara H, Miyagi Y, Tsuruyama T, Taguchi K, Katoh H, Takeuchi T, Gotoh M, Kuramoto J, Arai E, Ojima H, Shibuya A, Yoshida T, Akahane T, Kasajima R, Morita KI, Inazawa J, Sasaki T, Fukayama M, Oda Y. The Japanese Society of Pathology Guidelines on the handling of pathological tissue samples for genomic research: Standard operating procedures based on empirical analyse. Pathol Int 68(2):63-90, 2018.
  52. Masudo K, Suganuma N, Nakayama H, Oshima T, Rino Y, Iwasaki H, Matsuzu K, Sugino K, Ito K, Kondo T, Nakamura Y, Yoshihara M, Masuda M, Miyagi Y. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer. In Vivo 32(1):25-31, 2018.
  53. Baghdadi M, Endo H, Takano A, Ishikawa K, Kameda Y, Wada H, Miyagi Y, Yokose T, Ito H, Nakayama H, Daigo Y, Suzuki N, Seino KI. High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Sci Rep 8(1):418, 2018. doi: 10.1038/s41598-017-18796-8.
  54. Okubo Y, Kasajima R, Suzuki M, Miyagi Y, Motohashi O, Shiozawa M, Yoshioka E, Washimi K, Kawachi K, Kameda Y, Yokose T. Risk factors associated with the progression and metastases of hindgut neuroendocrine tumors: a retrospective study. BMC Cancer 17(1):769, 2017. doi: 10.1186/s12885-017-3769-4.
  55. Suzuki-Shibata S, Yamamoto Y, Yoshida T, Mizoguchi N, Nonaka T, Kubota A, Narimatsu H, Miyagi Y, Kobayashi T, Kaneta T, Inoue T. Prognostic value of volumetric FDG PET/CT parameters in patients with oral tongue squamous cell carcinoma who were treated by superselective intra-arterial chemoradiotherapy. Jpn J Radiol 35(12):740-747, 2017. doi: 10.1007/s11604-017-0686-z.
  56. Tetsuya Isaka, Tomoyuki Yokose, Yohei Miyagi, Kota Washimi, Teppei Nishii, Hiroyuki Ito, Haruhiko Nakayama, Kouzo Yamada and Munetaka.Detection of tumor spread through airspaces by airway secretion cytology from resected lung cancer specimens. Pathol Int 67(10):487-494, 2017. doi: 10.1111/pin.12570.
  57. Murakawa M, Aoyama T, Miyagi Y, Atsumi Y, Kazama K, Yamaoku K, Kanazawa A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Yamamoto N, Oshima T, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy. Oncol Lett 14(2):1505-1511, 2017. doi: 10.3892/ol.2017.6295.
  58. Suganuma N, Iwasaki H, Shimizu S, Yoshida T, Yamanaka T, Kojima I, Yamazaki H, Toda S, Nakayama H, Masudo K, Rino Y, Kawachi K, Miyagi Y, Miyake A, Ohashi K, Masuda M. Non-functioning parathyroid carcinoma: a case report. Surg Case Rep 3(1):81, 2017.
  59. Aoyama T, Kazama K, Miyagi Y, Murakawa M, Yamaoku K, Atsumi Y, Shiozawa M, Ueno M, Morimoto M, Oshima T, Yukawa N, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy. Oncol Lett 14(1):599-606, 2017.
  60. Goto H, Kitagawa N, Sekiguchi H, Miyagi Y, Keino D, Sugiyama M, Sarashina T, Miyagawa N, Yokosuka T, Hamanoue S, Iwasaki F, Shiomi M, Goto S, Tanaka Y. The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma. J Pediatr Hematol Oncol 39(5):395-401, 2017. doi: 10.1097/MPH.0000000000000865.
  61. Aoyama T, Miyagi Y, Murakawa M, Yamaoku K, Atsumi Y, Shiozawa M, Ueno M, Morimoto M, Oshima T, Yukawa N, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine. Oncol Lett 13(5):3423-3430, 2017. doi: 10.3892/ol.2017.5935.
  62. Kim H, Yamagishi A, Imaizumi M, Onomura Y, Nagasaki A, Miyagi Y, Okada T, Nakamura C. Quantitative measurements of intercellular adhesion between a macrophage and cancer cells using a cup-attached AFM chip. Colloids Surf B Biointerfaces 155: 366-372, 2017. http://doi.org/10.1016/j.colsurfb.2017.04.039
  63. Inari H, Suganuma N, Kawachi K, Yoshida T, Yamanaka T, Nakamura Y, Yoshihara M, Nakayama H, Masudo K, Oshima T, Yokose T, Rino Y, Shimizu S, Miyagi Y, Masuda M. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer. Breast Cancer 24(6):748-755, 2017. doi: 10.1007/s12282-017-0774-z.
  64. Tsuji S, Washimi K, Kageyama T, Yamashita M, Yoshihara M, Matsuura R, Yokose T, Kameda Y, Hayashi H, Morohoshi T, Tsuura Y, Yusa T, Sato T, Togayachi A, Narimatsu H, Nagasaki T, Nakamoto K, Moriwaki Y, Misawa H, Hiroshima K, Miyagi Y, Imai K. HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma. Sci Rep 7:45768, 2017. doi: 10.1038/srep45768.
  65. Inari H, Suganuma N, Kawachi K, Yoshida T, Yamanaka T, Nakamura Y, Yoshihara M, Nakayama H, Yamanaka A, Masudo K, Oshima T, Yokose T, Rino Y, Shimizu S, Miyagi Y, Masuda M. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions. BMC Cancer 17(1):160, 2017. doi: 10.1186/s12885-017-3154-3.
  66. Ariura M, Kasajima R, Miyagi Y, Ishidera Y, Sugo Y, Oi Y, Hayashi H, Shigeta H, Miyagi E. Combined large cell neuroendocrine carcinoma and endometrioid carcinoma of the endometrium: a shared gene mutation signature between the two histological components. Int Cancer Conference J 6(1): 11-15, 2017. DOI: 10.1007/s13691-016-0263-9.
  67. Masunaga A, Omatsu M, Kunimura T, Uematsu S, Kamio Y, Kitami A, Miyagi Y, Hiroshima K, Suzuki T. Expression of PTEN and its pseudogene PTENP1, and promoter methylation of PTEN in non-tumourous thymus and thymic tumours. J Clin Pathol 70(8):690-696, 2017.
  68. Seow WJ, Matsuo K, Hsiung CA, Shiraishi K, Song M, Kim HN, Wong MP, Hong YC, Dean Hosgood H 3rd, Wang Z, Chang IS, Wang JC, Chatterjee N, Tucker M, Wei H, Mitsudomi T, Zheng W, Kim JH, Zhou B, Caporaso NE, Albanes D, Shin MH, Ping Chung L, An SJ, Wang P, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Bassig BA, Chang J, Ho JC, Ji BT, Kubo M, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Sakamoto H, Kunitoh H, Tsuta K, Watanabe SI, Nokihara H, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Shi J, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Wong JY, Matsuda F, Su J, Kim YH, Oh IJ, Song F, Lee VH, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Yang PC, Lin HC, Xiang YB, Seow A, Yong Park J, Kweon SS, Chen CJ, Li H, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Wang WC, Chung CC, Lawrence C, Burdett L, Yeager M, Jacobs KB, Hutchinson A, Berndt SI, He X, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Hu L, Chen CH, Yang TY, Xu J, Guan P, Tan W, Wang CL, Sihoe AD, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Chan JK, Chu M, Li YJ, Li J, Chen H, Yu CJ, Jin L, Lo YL, Chen YH, Fraumeni JF Jr, Liu J, Yamaji T, Yang Y, Hicks B, Wyatt K, Li SA, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Li X, Ren Y, Cui P, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Wu G, Chien LH, Chen HL, Su YC, Tsai FY, Chen YS, Yu J, Stevens VL, Laird-Offringa IA, Marconett CN, Lin D, Chen K, Wu YL, Landi MT, Shen H, Rothman N, Kohno T, Chanock SJ, Lan Q. Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. Hum Mol Genet 26(2):454-465, 2017. doi: 10.1093/hmg/ddw414.
  69. Nishii T, Yokose T, Miyagi Y, Daigo Y, Isaka T, Furumoto H, Ito H, Murakami S, Kondo T, Saito H, Oshita F, Yamada K, Matsukuma S, Nakayama H, Masuda M. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma. Asia Pac J Clin Oncol 13(5):e204-e211, 2017. doi: 10.1111/ajco.12512.
  70. Samanta S, Tamura S, Dubeau L, Mhawech-Fauceglia P, Miyagi Y, Kato H, Lieberman R, Buckanovich RJ, Lin YG, Neamati N. Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. Oncotarget 8(61):103543-103556, 2017. doi: 10.18632/oncotarget.21569.
  71. Okubo Y, Motohashi O, Nakayama N, Nishimura K, Kasajima R, Miyagi Y, Shiozawa M, Yoshioka E, Suzuki M, Washimi K, Kawachi K, Nito M, Kameda Y, Yokose T. The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure. Diagn Pathol 11(1):128, 2016.
  72. Arakawa N, Kobayashi H, Yonemoto N, Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y, Hirahara F, Hirano H, Miyagi E. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma. PLoS One 11(10):e0165609, 2016. doi: 10.1371/journal.pone.0165609.
  73. Miyazaki K, Oyanagi J, Sugino A, Sato H, Yokose T, Nakayama H, Miyagi Y. Highly sensitive detection of invasive lung cancer cells by novel antibody against amino-terminal domain of laminin γ2 chain. Cancer Sci 107(12):1909-1918, 2016. doi: 10.1111/cas.13089.
  74. Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, Kaga K, Miyagi Y, Yokose T, Takano A, Daigo Y, Seino KI. Chemotherapy-induced IL-34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res 76(20):6030-6042, 2016.
  75. Isaka T, Nakayama H, Yokose T, Ito H, Miyagi Y, Matsuzaki T, Nagata M, Furumoto H, Nishii T, Katayama K, Yamada K, Masuda M. Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma. Ann Thorac Surg 102(6):1821-1828, 2016. doi: 10.1016/j.athoracsur.2016.06.001.
  76. Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, Kunitoh H, Matsumoto S, Takano A, Shimizu K, Goto A, Tsuta K, Watanabe S, Ohe Y, Watanabe Y, Goto Y, Nokihara H, Furuta K, Yoshida A, Goto K, Hishida T, Tsuboi M, Tsuchihara K, Miyagi Y, Nakayama H, Yokose T, Tanaka K, Nagashima T, Ohtaki Y, Maeda D, Imai K, Minamiya Y, Sakamoto H, Saito A, Shimada Y, Sunami K, Saito M, Inazawa J, Nakamura Y, Yoshida T, Yokota J, Matsuda F, Matsuo K, Daigo Y, Kubo M, Kohno T. Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. Nat Commun 7:12451, 2016. doi: 10.1038/ncomms12451.
  77. Karino F, Yokose T, Matsukuma S, Miyagi Y, Murakami S, Ito H, Nakayama H, Yamada K. Clonality analysis performed using human androgen receptor assay in a rare case of undifferentiated thymic carcinoma coexisting with type AB thymoma. Pathol Int 66(7):398-403, 2016. doi: 10.1111/pin.12426.
  78. Ishikawa T, Matsukuma S, Yoshihara M, Kurosawa T, Miyagi Y. Analysis of human androgen receptor polymorphism using fluorescent loop-hybrid mobility shift technique. Adv Tech Biol Med (not on PubMed) 4:2, 2016. doi: 10.4 172/2379-1764.1000174
  79. Ono K, Yokota NR, Yoshioka E, Noguchi A, Washimi K, Kawachi K, Miyagi Y, Kato H, Yokose T. Metastatic large cell neuroendocrine carcinoma of the lung arising from the uterus: A pitfall in lung cancer diagnosis. Pathol Res Pract 212(7):654-7, 2016. doi: 10.1016/j.prp.2016.03.009.
  80. Morinaga S, Nakamura Y, Atsumi Y, Murakawa M, Yamaoku K, Aoyama T, Kobayashi S, Ueno M, Morimoto M, Yokose T, Miyagi Y. Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy. Anticancer Res 36(3):1083-8, 2016.
  81. Okayama A, Kimura Y, Miyagi Y, Oshima T, Oshita F, Ito H, Nakayama H, Nagashima T, Rino Y, Masuda M, Ryo A, Hirano H. Relationship between phosphorylation of sperm-specific antigen and prognosis of lung adenocarcinoma. J Proteomics 139:60-6, 2016. doi: 10.1016/j.jprot.2016.03.005.
  82. Omata T, Nagai J, Shimbo H, Koizume S, Miyagi Y, Kurosawa K, Yamashita S, Osaka H, Inoue K. A splicing mutation of proteolipid protein 1 in Pelizaeus-Merzbacher disease. Brain Dev 38(6):581-4, 2016. doi: 10.1016/j.braindev.2015.12.002.
  83. Koizume S, Ito S, Yoshioka Y, Kanayama T, Nakamura Y, Yoshihara M, Yamada R, Ochiya T, Ruf W, Miyagi E, Hirahara F, Miyagi Y. High-level secretion of tissue factor-rich extracellular vesicles from ovarian cancer cells mediated by filamin-A and protease-activated receptors. Thromb Haemost 115 (2): 299-310, 2016.
  84. Oshita F, Kasajima R, Miyagi Y. Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer. J Exp Ther Oncol 11(3):189-194, 2016.
  85. Okayama A, Miyagi Y, Oshita F, Ito H, Nakayama H, Nishi M, Kurata Y, Kimura Y, Ryo A, Hirano H. Identification of tyrosine-phosphorylated proteins upregulated during epithelial-mesenchymal transition induced with TGF-β. J Proteome Res 14(10):4127-36, 2015. doi: 10.1021/acs.jproteome.5b00082.
  86. Koizume S, Miyagi Y. Anti-apoptotic genes are synergistically activated in OVSAYO cells cultured under conditions of serum starvation and hypoxia. Genomics Data 5:129-131, 2015. doi:10.1016/j.gdata.2015.05.029
  87. Chijiwa T, Kawai K, Noguchi A, Sato H, Hayashi A, Cho H, Shiozawa M, Kishida T, Morinaga S, Yokose T, Katayama M, Takenaka N, Suemizu H, Yamada R, Nakamura Y, Takano Y, Miyagi Y*, Nakamura M*. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Int J Oncol 47: 61-70, 2015. doi: 10.3892/ijo.2015.2997. *co-corespondence
  88. Kikuchi K, Noguchi A, Kasajima R, Miyagi Y, Hoshino D, Koshikawa N, Kubota A, Yokose T, Takano Y. Tumour Biol 36(10):7865-72, 2015.
  89. Koizume S, Ito S, Nakamura Y, Yoshihara M, Furuya M, Yamada R, Miyagi E, Hirahara F, Takano Y, Miyagi Y. Lipid starvation and hypoxia synergistically activate ICAM1 and multiple genes in an Sp1-dependent manner to promote the growth of ovarian cancer. Mol Cancer 14(1):77. doi: 10.1186/s12943-015-0351-z.
  90. Wada H, Shiozawa M, Katayama K, Okamoto N, Miyagi Y, Rino Y, Masuda M, Akaike M. Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer. J Gastroenterol 50(7): 727-34, 2015. doi: 10.1007/s00535-015-1057-0.
  91. Asano R, Asai-Sato M, Miyagi Y, Mizushima T, Koyama-Sato M, Nagashima Y, Taguri M, Sakakibara H, Hirahara F, Miyagi E. Aberrant expression of erythropoietin in uterine leiomyomas and its implication in tumor growth. Am J Obstet Gynecol 213(2):199.e1-8, 2015. doi: 10.1016/j.ajog.2015.02.016.
  92. Nagata K, Kawakami T, Kurata Y, Kimura Y, Suzuki Y, Nagata T, Sakuma Y, Miyagi Y, Hirano H. Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis. J Proteomics 115:132-42, 2015. doi: 10.1016/j.jprot.2014.12.012.
  93. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 64(11):1721-31, 2015. doi: 10.1136/gutjnl-2014-308252.
  94. Funauchi Y, Tanikawa C, Yi Lo PH, Mori J, Daigo Y, Takano A, Miyagi Y, Okawa A, Nakamura Y, Matsuda K. Regulation of iron homeostasis by the p53-ISCU pathway. Sci Rep 5:16497, 2015. doi: 10.1038/srep16497.
  95. Ono K, Hayashi H, Tateno M, Tanaka R, Suzuki R, Maruyama Y, Miyagi Y, Furuya M. Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: clinicopathological analysis of 6 patients. Int J Clin Exp Pathol 7(11):7979-88, 2014.
  96. Nishii T, Yokose T, Miyagi Y, Daigo Y, Ito H, Isaka T, Imai K, Murakami S, Kondo T, Saito H, Oshita F, Yamada K, Matsukuma S, Tsuboi M, Nakayama H, Masuda M. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer. BMC Cancer 14(1):610, 2014. doi:10.1186/1471-2407-14-610.
  97. Noguchi A, Kikuchi K, Zheng H, Takahashi H, Miyagi Y, Aoki I, Takano Y. SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med 3(6):1553-61, 2014. doi: 10.1002/cam4.310.
  98. Kim H, Terazono H, Nakamura Y, Sakai K, Hattori A, Odaka M, Girault M, Arao T, Nishio K, Miyagi Y, Yasuda K. Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells. PLoS One 9(8):e104372, 2014. doi: 10.1371/journal.pone.0104372.
  99. Harada T, Saito H, Karino F, Isaka T, Murakami S, Kondo T, Oshita F, Miyagi Y, Yamada K. Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy. Mol Clin Oncol 2(5):737-743, 2014.
  100. Okudela K, Suzuki T, Umeda S, Tateishi Y, Mitsui H, Miyagi Y, Ohashi K. A comprehensive search for microRNAs with expression profiles modulated by oncogenic KRAS: Potential involvement of miR-31 in lung carcinogenesis. Oncol Rep 32(4):1374-84, 2014. doi: 10.3892/or.2014.3339.
  101. Okayama A, Miyagi Y, Oshita F, Nishi M, Nakamura Y, Nagashima Y, Akimoto K, Ryo A, Hirano H. Proteomic Analysis of Proteins Related to Prognosis of Lung Adenocarcinoma. J Proteome Res 13(11):4686-94, 2014. doi: 10.1021/pr4012969.
  102. Okudela K, Tateishi Y, Umeda S, Mitsui H, Suzuki T, Saito Y, Woo T, Tajiri M, Masuda M, Miyagi Y, Ohashi K. Allelic Imbalance in the miR-31 Host Gene Locus in Lung Cancer - Its Potential Role in Carcinogenesis. PLoS One 30;9(6):e100581, 2014. doi: 10.1371/journal.pone.0100581. 
  103. Kobayashi Y, Takano A, Miyagi Y, Tsuchiya E, Sonoda H, Shimizu T, Okabe H, Tani T, Fujiyama Y, Daigo Y. Cell division cycle-associated protein 1 overexpression is essential for the malignant potential of colorectal cancers. Int J Oncol 44(1):69-77, 2014. doi: 10.3892/ijo.2013.2177.
  104. Suzuki Y, Miyagi Y, Yukawa N, Rino Y, Masuda M. Epigenetic silencing of checkpoint with fork-head associated and ring finger gene expression in esophageal cancer. Oncol Lett 7(1):69-73, 2014. doi:10.3892/ol.2013.1677
  105. Komiya E, Sato H, Watanabe N, Ise M, Higashi S, Miyagi Y, Miyazaki K. Angiomodulin, a marker of cancer vasculature, is upregulated by vascular endothelial growth factor and increases vascular permeability as a ligand of integrin αvβ3. Cancer Med 3(3):537-49, 2014. doi: 10.1002/cam4.216.
  106. Numata M, Morinaga S, Watanabe T, Tamagawa H, Yamamoto N, Shiozawa M, Nakamura Y, Kameda Y, Okawa S, Rino Y, Akaike M, Masuda M, Miyagi Y. The clinical significance of SWI/SNF complex in pancreatic cancer. Int J Oncol 42(2):403-10, 2013.
  107. Okudela K, Woo T, Mitsui H, Suzuki T, Tajiri M, Sakuma Y, Miyagi Y, Tateishi Y, Umeda S, Masuda M, Ohashi K. Downregulation of ALDH1A1 expression in non-small cell lung carcinomas - its clinicopathologic and biological significance. Int J Clin Exp Pathol 6(1):1-12, 2013.
  108. Noguchi A, Li X, Kubota A, Kikuchi K, Kameda Y, Zheng H, Miyagi Y, Aoki I, Takano Y. SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol 115(3):385-92, 2013.
  109. van Grieken NC, Aoyma T, Chambers TA, Bottomley D, Ward LC, Inam I, Buffart TE, Das K, Lim T, Pang B, Zhang SL, Tan IB, Carvalho B, Heideman DAM, Miyagi Y, Kameda Y, Arai T, Meijer GA, Tsuburaya A, Tan P, Yoshikawa Y, Grabsch HI. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study. British J Cancer 108(7):1495-501, 2013.
  110. Tamagawa H, Oshima T, Numata M, Yamamoto N, Shiozawa M, Morimnaga S, Nakamura Y, Yoshihara M, Sakuma Y, Kameda Y, Akaike M, Yukawa N, Rino Y, Masuda M, Miyagi Y. Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. Eur J Surg Oncol 39(6):655-61, 2013.
  111. Enokida Y, Shimizu K, Atsumi J, Lezhava A, Tanaka Y, Kimura Y, Soma T, Hanami T, Kawai Y, Usui K, Okano Y, Kakegawa S, Ogawa H, Miyamae Y, Miyagi Y, Nakayama H, Ishikawa T, Hayashizaki Y, Takeyoshi I. Rapid Detection of SNP (c.309T>G) in the MDM2 Gene by the Duplex SmartAmp Method. PLoS ONE 8(4):e60151, 2013.
  112. Tarao K, Ohkawa S, Miyagi Y, Morinaga S, Ohshige K, Yamamoto N, Ueno M, Kobayashi S, Kameda R, Tamai S, Nakamura Y, Miyakawa K, Kameda Y, Okudaira M. Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis. Scand J Gastroenterol 248(6): 729-735, 2013.
  113. Yoshii T, Miyagi Y, Nakamura Y, Kobayashi O, Kameda Y, Ohkawa S. Pilot research for the correlation between the expression pattern of E-cadherin-β-catenin complex and lymph node metastasis in early gastric cancer. Tumori 99(2):234-8, 2013.
  114. Aoyama T, Yoshikawa T, Miyagi Y, Kameda Y, Shirai J, Hayashi T, Cho H, Oshima T, Yukawa N, Rino Y, Masuda M, Tsuburaya A. Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. Surg Today 43(12):1390-7, 2013.
  115. Wada H, Shiozawa M, Sugano N, Morinaga S, Rino Y, Masuda M, Akaike M, Miyagi Y. Lymphatic invasion identified with D2-40 immunostaining as a risk factor of nodal metastasis in T1 colorectal cancer. Int J Clin Oncol 18(6):1025-31, 2013.
  116. Arakawa N, Miyagi E, Nomura A, Morita E, Ino Y, Ohtake N, Miyagi Y, Hirahara F, Hirano H. Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. J Proteome Res 12(10):4340-50, 2013.
  117. Sakuma Y, Matsukuma S, Nakamura Y, Yoshihara M, Koizume S, Sekiguchi H, Saito H, Nakayama H, Kameda Y, Yokose T, Oguni S, Niki T, Miyagi Y. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. Lab Invest 93(10):1137-46, 2013.
  118. Okano Y, Nezu U, Enokida Y, Lee MT, Kinoshita H, Lezhava A, Hayashizaki Y, Morita S, Taguri M, Ichikawa Y, Kaneko T, Natsumeda Y, Yokose T, Nakayama H, Miyagi Y, Ishikawa T. SNP (-617C>A) in ARE-Like Loci of the NRF2 Gene: A New Biomarker for Prognosis of Lung Adenocarcinoma in Japanese Non-Smoking Women. PLoS ONE 8(9):e73794, 2013.
  119. Noguchi A, Kikuchi K, Ohtsu T, Yoshiwara M, Nakamura Y, Miyagi Y, Zheng H, Takano Y. Pulmonary tumors associated with the JC virus T-antigen in a transgenic mouse model. Oncol Rep 30(6):2603-8, 2013.
  120. Mogami T, Yokota N, Asai-Sato M, Yamada R, Koizume S, Sakuma Y, Yoshihara M, Nakamura Y, Takano Y, Hirahara F, Miyagi Y, Miyagi E. Annexin A4 Is Involved in Proliferation, Chemo-Resistance and Migration and Invasion in Ovarian Clear Cell Adenocarcinoma Cells. PLoS ONE 8(11):e80359, 2013. Doi:10.1371/journal.pone.0080359
  121. Hayashi H, Miyagi Y, Sekiyama A, Yoshida S, Nakao S, Okamoto N, Koganei K, Sugita A. Colorectal small cell carcinoma in ulcerative colitis with identical p53 gene mutation to associated adenocarcinoma and dysplasia. J Crohns Colitis 6(1):112-5, 2012.
  122. Tamagawa H, Oshima T, Shiozawa M, Morinaga S, Nakamura Y, Yoshihara M, Sakuma Y, Kameda Y, Akaike M, Masuda M, Imada T, Miyagi Y. The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep 27(3):637-42, 2012.
  123. Tamagawa H, Miyagi Y, Numata M, Yamamoto N, Shiozawa M, Morinaga S, Sekiyama A, Sekiguchi H, Sakuma Y, Kameda Y, Akaike M, Masuda M, Imada T. Comparison of the chemosensitivity of the primary lesion and a pancreatic metastasis of colon cancer: a case report. Anticancer Res 32(4):1457-61, 2012.
  124. Komiya E, Furuya M, Watanabe N, Miyagi Y, Higashi S, Miyazaki K. Elevated expression of angiomodulin in tumor stroma and its roles in fibroblast activation. Elevated expression of angiomodulin (AGM/IGFBP-rP1) in tumor stroma and its roles in fibroblast activation. Cancer Sci 103(4): 691-9, 2012.
  125. Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, Yokose T, Kameda Y, Koizume S, Miyagi Y. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest 92(3):371-83, 2012.
  126. Endoh K, Nishi M, Ishiguro H, Uemura H, Miyagi Y, Aoki I, Hirano H, Kubota Y, Ryo A. Identification of phosphorylated proteins involved in the oncogenesis of prostate cancer via Pin1-proteomic analysis. Prostate 72(6):626-37, 2012.
  127. Ohe M, Yokose T, Sakuma Y, Miyagi Y, Okamoto N, Osanai S, Hasegawa C, Nakayama H, Kameda Y, Yamada K, Isobe T. Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinom. Diagn Pathol 7:3, 2012.
  128. Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Ohkawa S, Kameda Y, Miyagi Y. Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy. Ann Surg Oncol 19(3):558-564, 2012.
  129. Furuya M, Tanaka R, Miyagi E, Kami D, Nagahama K, Miyagi Y, Nagashima Y, Hirahara F, Inayama Y, Aoki I. Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis. Cancer Biol Ther 13(8): 671-680, 2012.
  130. Cho H, Watanabe T, Aoyama T, Hayashi T, Yamada T, Ogata T, Yoshikawa T, Tsuburaya A, Sekiguchi H, Nakamura Y, Sakuma Y, Kameda Y, Miyagi Y. Small bud of probable gastrointestinal stromal tumor within a laparoscopically-resected gastric schwannoma. Int J Clin Oncol 17(3):294-298, 2012.
  131. Koizume S, Ito S, Miyagi E, Hirahara F, Nakamura Y, Sakuma Y, Osaka H, Takano Y, Ruf W, Miyagi Y. HIF2α-Sp1 interaction mediates a deacetylation-dependent FVII gene activation under hypoxic conditions in ovarian cancer cells. Nucleic Acid Res 40(12):5389-5401, 2012.
  132. Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y, Koizume S, Okamoto N, Kondo T, Masuda M, Miyagi Y. The association between RAS gene mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 22(7):683-689, 2012.
  133. Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Koizume S, Miyagi Y. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells. Biochem Biophys Res Commun 423(4):667-671, 2012.
  134. Washimi K, Yokose T, Yamashita M, Kageyama T, Suzuki K, Yoshihara M, Miyagi Y, Hayashi H, Tsuji S. Specific Expression of Human Intelectin-1 in Malignant Pleural Mesothelioma and Gastrointestinal Goblet Cells. PLoS ONE 7(7):e39889. doi:10.1371/journal.pone.0039889, 2012.
  135. Tarao K, Miyakawa K, Miyagi Y, Ohkawa S, Morinaga S, Oshige K, Yamamoto N, Ueno M, Kobayashi S, Kameda R, Tamai S, Nakamura Y, Endo Y, Kameda Y, Okudaira M. Severe Inflammation in the Background Liver Cirrhosis Correlates with the Development of Poorly Differentiated HCC in HCV-Associated Liver Cirrhosis. Intern Med 51(18):2495-501, 2012.
  136. Watanabe T, Morinaga S, Akaike M, Numata M, Tamagawa H, Yamamoto N, Shiozawa M, Ohkawa S, Kameda Y, Nakamura Y, Miyagi Y. The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery. Eur J Surg Oncol 38(11):1051-7, 2012. doi: 10.1016/j.ejso.2012.08.008.
  137. Asai-Sato M, Hayashi H, Miyagi Y, Takahashi M, Shigeta H. An inconspicuous fallopian-tube carcinoma clinically manifested as a rectovaginal septal tumor: a pitfall for diagnosis and treatment. Int J Clin Oncol 16(2):161-4, 2011.
  138. Sakuma Y, Tsunezumi J, Nakamura Y, Yoshihara M, Matsukuma S, Koizume S, Miyagi Y. ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. Oncol Rep 25(3):661-7, 2011.
  139. Suda T, Yoshihara M, Nakamura Y, Sekiguchi H, Godai TI, Sugano N, Tsuchida K, Shiozawa M, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M, Matsukuma S, Miyagi Y. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable. Oncol Rep 26(1):49-54, 2011.
  140. Mori T, Kariya Y, Komiya E, Higashi S, Miyagi Y, Sekiguchi K, Miyazaki K. Down-regulation of a newly identified laminin, laminin-3B11, in vascular basement membranes of invasive human breast cancers. Cancer Sci 102(5):1095-100, 2011.
  141. Matsukuma S, Saito H, Yamada K, Okamoto N, Ishikawa T, Yoshihara M, Koizume S, Sakuma Y, Miyagi Y. Simple and precise detection of UGT1A1 polymorphisms with a modified loop-hybrid mobility shift assay using Cy5-labeled loop probes. Clin Chim Acta 412(17-18):1668-72, 2011.
  142. Furuya M, Yoneyama T, Miyagi E, Tanaka R, Nagahama K, Miyagi Y, Nagashima Y, Hirahara F, Inayama Y, Aoki I. Differential Expression Patterns of CXCR3 Variants and Corresponding CXC Chemokines in Clear Cell Ovarian Cancers and Endometriosis. Gynecol Oncol 122(3):648-55 2011.
  143. Matsukuma S, Yoshihara M, Suda T, Shiozawa M, Akaike M, Ishikawa T, Koizume S, Sakuma Y, Miyagi Y. Differential detection of KRAS mutations in codons 12 and 13 with a modified loop-hybrid (LH) mobility shift assay using an insert-type LH-generator. Clin Chim Acta 412:1874-78, 2011.
  144. Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. Identification of Epstein-Barr Virus-Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer. Clin Cancer Res 17(19):6272-6286, 2011.
  145. Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, Saruki N, Bando E, Kimura H, Imamura F, Moriyama M, Ikeda I, Chiba A, Oshita F, Imaizumi A, Yamamoto H, Miyano H, Horimoto K, Tochikubo O, Mitsushima T, Yamakado M, Okamoto N. Plasma free amino Acid profiling of five types of cancer patients and its application for early detection. PLoS ONE 6(9):e24143, 2011.
  146. Ogane N, Yasuda M, Shimizu M, Miyazawa M, Kamoshida S, Ueda A, Takata K, Sakuma Y, Miyagi Y, Kameda Y. Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol 14(1):23-29, 2010.
  147. Ichikawa Y, Miyagi Y, Fujii S, Ota M, Yamagishi S, Hasegawa S, Saito S, Ike H, Ohki S, Nakano A, Matsumura N, Ishikawa T, Kunizaki C, Shimada H. Gastrointestinal stromal tumor with two genetic abnormalities on different alleles: Report of a case. Surg Today 40(3):262-6, 2010.
  148. Sakuma Y, Takeuchi T, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, Ohgane N, Yokose T, Kameda Y, Tsuchiya E, Miyagi Y. Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis with Mcl-1 and E-cadherin expression. J Pathol 220(5):574-585, 2010.
  149. Sugano N, Suda T, Godai T, Tsuchida K, Shiozawa M, Sekiguchi H, Yoshihara M, Matsukuma S, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M, Miyagi Y. MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis. Genes Chromosomes Cancer 49(7): 620-629, 2010.
  150. Okada A, Shimmyo T, Hashimoto T, Kobayashi Y, Miyagi Y, Ishikawa Y, Nakagawa K, Hayashi J, Tsuchiya E. Predictive advantage of a cell type classification for pulmonary adenocarcinoma coupled with data for p53, K-ras and EGFR alterations. Cancer Sci 101(7):1745-753, 2010.
  151. Oshita F, Morita A, Ito H, Kameda Y, Tsuchiya E, Asai S, Miyagi Y. Proteomic screening of completely resected tumors in relation to survival in patients with stage I non-small cell lung cancer. Oncol Rep 24(3):637-45, 2010.
  152. Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, Ishikawa N, Kohno N, Ito H, Miyamoto M, Nakayama H, Miyagi Y, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y. Wnt Inhibitor Dickkopf-1 as a Target for Passive Cancer Immunotherapy. Cancer Res 70(13):5326-36 2010.
  153. Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol 23(11):1492-8, 2010.
  154. Tsuji S, Tsuura Y, Morohoshi T, Shinohara T, Oshita F, Yamada K, Kameda Y, Ohtsu T, Nakamura Y, Miyagi Y. Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion. Br J Cancer 103(4):517-23 2010.
  155. Oshita F, Miyagi Y, Honda T, Murakami S, Kondo T, Saito H, Noda K, Yokose T, Kameda Y, Sakuma Y, Obata M, Yamada K. Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status. J Exp Ther Oncol 8(4):313-9, 2010.
  156. Ueda K, Fukase Y, Katagiri T, Ishikawa N, Irie S, Sato TA, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Shiwa M, Nakamura Y, Daigo Y. Targeted serum glycoproteomics for the discovery of lung cancer-associated glycosylation disorders using lectin-coupled ProteinChip arrays. Proteomics 9(8):2182-92, 2009.
  157. Sakuma Y, Okamoto N, Saito H, Yamada K, Yokose T, Kiyoshima M, Asato Y, Amemiya R, Saitoh H, Matsukuma S, Yoshihara M, Nakamura Y, Oshita F, Ito H, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y. A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2cm or less in size. Lung Cancer 65(1):85-90, 2009.
  158. Araki N, Ishigami T, Ushio H, Minegishi S, Umemura M, Miyagi Y, Aoki I, Morinaga H, Tamura K, Toya Y, Uchino K, Umemura S. Identification of NPC2 protein as interaction molecule with C2 domain of human Nedd4L. Biochem Biophys Res Commun 388(2):290-6, 2009.
  159. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 69(16):6694-703, 2009.
  160. Yokota N, Koizume S, Miyagi E, Hirahara F, Nakamura Y, Kikuchi K, Ruf W, Sakuma Y, Tsuchiya E, Miyagi Y. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer 101, 2023-2029, 2009.
  161. Koizume S, Yokota N, Miyagi E, Hirahara F, Nakamura Y, Sakuma Y, Yoshida A, Kameda Y, Tsuchiya E, Ruf W, Miyagi Y. HNF-4 independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases. Mol Cancer Res 7(12):1928-36, 2009.
  162. Godai T, Suda T, Sugano N, Tsuchida K, Shiozawa M, Sekiguchi H, Sekiyama A, Yoshihara M, Matsukuma S, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M, Miyagi Y. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer 9(1):420, 2009.
  163. Okamoto N, Miyagi Y, Chiba A, Akaike M, Shiozawa M, Imaizumi A, Yamamoto H, Ando T, Yamakado M, Tochikubo O. Diagnostic modeling with differences in plasma amino acid profiles between non-cachectic colorectal/breast cancer patients and healthy individuals. Int J Medicine Medical Sci (not on PubMed) 1:1-8, 2009.
  164. Sakuma Y, Matsukuma S, Yoshihara M, Sakurai S, Nishii M, Kishida T, Kubota Y, Nagashima Y, Inayama Y, Sasaki T, Nakamura Y, Miura T, Kameda Y, Tsuchiya E, Miyagi Y. Mutations of c-kit gene in bilateral testicular germ cell tumours in Japan. Cancer Lett 259: 119-126, 2008.
  165. Amin RM, Hiroshima K, Miyagi Y, Kokubo T, Hoshi K, Fujisawa T, Nakatani Y. Role of the PI3K/Akt, mTOR, and STK11/LKB1 pathways in the tumorigenesis of sclerosing hemangioma of the lung. Pathol Int 58(1):38-44, 2008.
  166. Amin RM, Hiroshima K, Iyoda A, Hoshi K, Honma K, Kuroki M, Kokubo T, Fujisawa T, Miyagi Y, Nakatani Y. LKB1 protein expression in neuroendocrine tumors of the lung. Pathol Int 58 (2):84–88, 2008.
  167. Shimmyo T, Okada A, Hashimoto T, Kobayashi Y, Miyagi Y, Ishikawa Y, Nakagawa K, Osada H, Tsuchiya E. Etiologic value of p53 mutation spectra and differences with histology in lung cancers. Cancer Sci 99(2):287–95, 2008.
  168. Araki N, Umemura M, Miyagi Y, Yabana M, Miki Y, Tamura K, Uchino K, Aoki R, Goshima Y, Umemura S, Ishigami T. Expression, Transcription, and Possible Antagonistic Interaction of the Human Nedd4L Gene Variant. Implications for Essential Hypertension. Hypertension 51(3):773-7. 2008.
  169. Wada N, Yoshida A, Miyagi Y, Yamamoto T, Nakayama H, Suganuma N, Matsuzu K, Masudo K, Hirakawa S, Rino Y, Masuda M, Imada T. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Res 28(1A):139-44, 2008.
  170. Koizume S, Yokota N, Miyagi E, Hirahara F, Tsuchiya E, Miyagi Y. Heterogeneity in binding and gene-expression regulation by HIF-2alpha. Biochem Biophys Res Commun 371(2):251-5, 2008.
  171. Oshiro H, Miyagi Y, Kawaguchi Y, Rino Y, Arai H, Asai-Sato M, Nakayama H, Yamanaka S, Inayama Y, Fukushima N. Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm. Pathol Int 58(7):456-61, 2008.
  172. Chimeddorj B, Pak CY, Damdin A, Okamoto N, Miyagi Y. Distribution of HPV-16 Intratypic Variants among Women with Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer in Mongolia. Asian Pac J Cancer Prev 9(4):563-8, 2008.
  173. Murata A, Miyagi Y, Osoegawa T, Tanaka M, Nakamura K. Detection of retroperitoneal fistula of the colon by CT colonography. Indian J Gastroenterol 27(6):256, 2008.
  174. Udaka N, Miyagi Y, Ito T. Connexin expression in mouse lung tumor. Cancer Lett 246(1-2):224-9, 2007.
  175. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y. Distinctive Evaluation of Non-mucinous and Mucinous Subtypes of Bronchioloalveolar Carcinomas in EGFR and K-ras Gene Mutation Analyses for Japanese Lung Adenocarcinomas: Confirmation of Correlations Between Histological Subtypes and Gene Mutations. Am J Clin Pathol 128(1):100-8, 2007.
  176. Watanabe-Kaneko K, Sonoda T, Miyagi Y, Yamashita T, Okuda K, Kawamoto S. The synaptic scaffolding protein Delphilin interacts with monocarboxylate transporter 2. Neuroreport 18(5):489-93, 2007.
  177. Nobeyama Y, Okochi-TakadaE, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, Nakanishi Y, Nakagawa H, Ushijima T. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 121(2):301-7, 2007.
  178. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Kondo S, Nakamura Y, Daigo Y. Dikkopf-1 as a Novel Serological and Prognostic Biomarker for Lung and Esophageal Carcinomas. Cancer Res 67(6):2517-25, 2007.
  179. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod Pathol 20(9):967-73, 2007.
  180. Nakajima T, Yasufuku K, Suzuki M, Hiroshima K, Kubo R, Mohammed S, Miyagi Y, Matsukuma S, Sekine Y, Fujisawa T. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 132(2):597-602, 2007.
  181. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27(5B):3645-9, 2007.
  182. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 67(24):11601-11, 2007.
  183. Umemura M, Ishigami T, Tamura K, Sakai M, Miyagi Y, Nagahama K, Aoki I, Uchino K, Rohrwasser A, Lalouel JM, Umemura S. Transcriptional diversity and expression of NEDD4L gene in distal nephron. Biochem Biophys Res Commun 339(4), 1129-37, 2006.
  184. Shimmyo T, Hashimoto T, Kobayashi Y, Miyagi Y, Ishikawa Y, Nakagawa K, Osada H, Tsuchiya E. p53 mutation spectra for squamous cell carcinomas at different levels of human bronchial branches. Int J Cancer 119(3):501-7, 2006.
  185. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Miyagi Y. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer. Gastric Cancer 9(2):106-13, 2006.
  186. Yoshikawa T, Tsuburaya A, Miyagi Y, Sekiguchi H, Kimura M, Cho H, Kobayashi O. Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. Anticancer Res 26(5B):3849-53, 2006.
  187. Oshita F, Sekiyama A, Ito H, Kameda Y, Miyagi Y. Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer. Oncol Rep 16(4):817-21, 2006.
  188. Koizume S, Takizawa S, Fujita K, Aida N, Yamashita S, Miyagi Y, Osaka H. Aberrant trafficking of a proteolipid protein in a mild pelizaeus-merzbacher disease. Neuroscience 141(4):1861-1869, 2006.
  189. Matsukuma S, Yoshihara M, Kasai F, Kato A, Yoshida A, Akaike M, Kobayashi O, Nakayama H, Sakuma Y, Yoshida T, Kameda Y, Tsuchiya E, Miyagi Y. Rapid and Simple Detection of Hot Spot Point Mutations of Epidermal Growth Factor Receptor, BRAF, and NRAS in Cancers Using the Loop-Hybrid Mobility Shift Assay. J Mol Diagn 8: 504-512, 2006.
  190. Yamamoto T, Sekiyama A, Sekiguchi H, Yoshida T, Miyagi Y. Examination of Stability of Bone Marrow Blood RNA in the PAXgene Tube. Lab Hematol 12(3):143-7, 2006.
  191. Koizume S, Jin MS, Miyagi E, Hirahara F, Nakamura Y, Piao JH, Asai A, Yoshida A, Tsuchiya E, Ruf W, Miyagi Y. Activation of Cancer Cell Migration and Invasion by Ectopic Synthesis of Coagulation Factor VII. Cancer Res 66(19):9453-60, 2006.
  192. Sonoda T, Mochizuki C, Yamashita T, Watanabe-Kaneko K, Miyagi Y, Shigeri Y, Yazama F, Okuda K, Kawamoto S. Binding of glutamate receptor delta2 to its scaffold protein, Delphilin, is regulated by PKA. Biochem Biophys Res Commun 350:748-52, 2006.
  193. Oshita F, Matsukuma S, Yoshihara M, Sakuma Y, Ohgane N, Kameda Y, Saito H, Yamada K, Tsuchiya E, Miyagi Y. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Br J Cancer 95, 1070-5, 2006.
  194. Yoshikawa T, Yanoma S, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Miyagi Y, Morinaga S, Noguchi Y, Yamamoto Y. Expression of MMP-7 and MT1-MMP in peritoneal dissemination of gastric cancer. Hepatogastroenterol 53(72):964-7, 2006.
  195. Ogawa M, Yanoma S, Nagashima Y, Okamoto N, Ishikawa H, Haruki A, Miyagi E, Takahashi T, Hirahara F, Miyagi Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with gylpican-3 hold the key. Placenta 28(2-3):224-32, 2006.
  196. Oshita F, Sekiyama A, Saito H, Yamada K, Noda K, Miyagi Y. Genome-wide cDNA microarray screening of genes related to the benefits of paclitaxel and irinotecan chemotherapy in patients with advanced non-small cell lung cancer. J Exp Ther Oncol 6(1):49-53, 2006.
  197. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, Goggins M. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 24(5):850-8, 2005.
  198. Tang X, Yamanaka S, Miyagi Y, Nagashima Y, Nakatani Y. Lung pathology of pale ear mouse (model of Hermansky-Pudlak syndrome 1) and beige mouse (model of Chediak-Higashi syndrome): Severity of giant lamellar body degeneration of type II pneumocytes correlates with interstitial inflammation. Pathol Int 55(3):137-43, 2005.
  199. Oshita F, Ikehara M, Sekiyama A, Hamanaka N, Saito H, Yamada K, Noda K, Kameda Y, Miyagi Y. Genome-wide cDNA microarray screening of genes related to benefits and toxicities of platinum-based chemotherapy in patients with advanced lung cancer. Am J Clin Oncol 28(4):367-70, 2005.
  200. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T, Osamura Y. Glucose transporter-1 expression in the thyroid gland: Clinicopathological significance for papillary carcinoma. Oncol Rep 14(6):1499-504, 2005.
  201. Yamashita T*, Miyagi Y*, Ono M, Ito H, Watanabe K, Sonoda T, Tsuzuki K, Ozawa S, Aoki I, Okuda K, Mishina M, Kawamoto S (*equally contributed). Identification and characterization of a novel Delphilin variant with an alternative N-terminus. Brain Res Mol Brain Res 141(1) 83-94, 2005.
  202. Cho H, Kobayashi O, Tsuburaya A, Sugiyama Y, Sairenji M, Motohashi H, Yoshida T, Miyagi Y, Imada T. Metastatic Gastrointestinal Stromal Tumor with an Exon 11 c-Kit Mutation Responding to the Tyrosine Kinase Inhibitor Imatinib. Dig Surg 21(1):74-77, 2004.
  203. Ikehara M, Oshita F, Sekiyama A, Hamanaka N, Saito H, Yamada K, Noda K, Kameda Y, Miyagi Y. Genome-wide cDNA microarray screening to correlate gene expression profile with survival in patients with advanced lung cancer. Oncol Rep 11(5):1041-4, 2004.
  204. Kawano T, Nakamura Y, Yanoma S, Kubota A, Furukawa M, Miyagi Y, Tsukuda M. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer. Auris Nasus Larynx 31(1):35-41, 2004.
  205. Aharon A, Brenner B, Katz T, Miyagi Y, Lanir N. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thromb Haemost 92(4):776-86, 2004.
  206. Oshita F, Ikehara M, Sekiyama A, Hamanaka N, Saito H, Yamada K, Noda K, Kameda Y, Miyagi Y. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer. J Exp Ther Oncol 4(2):155-60, 2004.
  207. Oshita F, Sekiyama A, Suzuki R, Ikehara M, Yamada K, Saito H, Noda K, Miyagi Y. Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by promoter methylation and silencing of the retinoic acid receptor-beta. Oncol Rep 10(1):105-8, 2003.
  208. Sugiyama A, Miyagi Y, Komiya Y, Kurabe N, Kitanaka C, Kato N, Nagashima Y, Kuchino Y, Tashiro F. Forced expression of antisense 14-3-3{beta} RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis. Carcinogenesis 24(9):1549-59, 2003.
  209. Ruf W, Seftor E. A., Petrovan R. J., Weiss R. M., Gruman L. M., Margaryan N. V., Seftor R. E. B., Miyagi Y., Hendrix M. J. C. Differential Role of Tissue Factor Pathway Inhibitors 1 and 2 in Melanoma Vasculogenic Mimicry. Cancer Res 63: 5381-9, 2003.
  210. Miyagi Y, Yamashita T, Fukaya M, Sonoda T, Okuno T, Yamada K, Watanabe M, Nagashima Y, Aoki I, Okuda K, Mishina M, kawamoto S. Delphilin: a Novel PDZ- and Formin Homology-Domain Containing Protein, Which Synaptically Colocalizes and Interacts with Glutamate Receptor g J Neurosci 22(3):803-14, 2002.
  211. Kamiyama M, Ichikawa Y, Ishikawa T, Chishima T, Hasegawa S, Hamaguchi Y, Nagashima Y, Miyagi Y, Mitsuhashi M, Hyndman D, Hoffman RM, Ohki S, Shimada H. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther 9(2):197-201, 2002.
  212. Udagawa K, Yasumitsu H, Esaki M, Sawada H, Nagashima Y, Aoki I, Jin M, Miyagi E, Nakazawa T, Hirahara F, Miyazaki K, and Miyagi Y. Subcellular localization of PP5/TFPI-2 in human placenta: A possible role of PP5/TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts. Placenta 23(2-3):145-53, 2002.
  213. Nakatani Y, Masudo K, Miyagi Y, Inayama Y, Kawano N, Tanaka Y, Kato K, Ito T, Kitamura H, Nagashima Y, Yamanaka S, Nakamura N, Sano J, Ogawa N, Ishiwa N, Notohara K, Resl M, Mark EJ. Aberrent nuclear localization and gene mutation of B-catenin in low-grade adenocarcinoma of fetal lung type: Up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod Pathol 15(6):617-24, 2002.
  214. Kikuchi M, Kitamura K, Nishio Y, Ishii M, Kawano N, Inayama Y, Miyagi Y, Nozawa A, Nakatani Y. Diagnosis of B-cell lymphoma. Utility of the polymerase chain reaction for detecting clonality from archival cytologic smears. Acta Cytol 46(2):349-56, 2002.
  215. Mizushima H, Hirosaki T, Miyata S, Takamura H, Miyagi Y, Miyazaki K. Expression of laminin-5 enhances tumorigenicity of human fibrosarcoma cells in nude mice. Jpn J Cancer Res 93(6):652-9, 2002.
  216. Tadokoro K, Koizumi Y, Miyagi Y, Kojima Y, Kawamoto S, Hamajima K, Okuda K, Tanaka S, Onari K, Wahren B, Aoki I, Okuda K. Rapid and wide-reaching delivery of HIV-1 env DNA vaccine by intranasal administration. Viral Immunol 14(2):159-67, 2001.
  217. Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, Kawamoto S, Ishii N, Yoshida T, Hanashi D, Koshino T, Okada H, Okuda K. Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. Immunology 103(1):98-105, 2001.
  218. Jin M, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Yasumitsu H, Miyazaki K, Nagashima Y, Aoki I, Miyagi Y. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 83(2):325-33, 2001.
  219. Noguchi Y, Saito A, Miyagi Y, Yamanaka S, Marat D, Doi C, Yoshikawa T, Tsuburaya A, Ito T, Satoh S. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett 154(2):175-182, 2000.
  220. Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LV, Ruf W. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 20(3):874-82, 2000.
  221. Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S, Okuda K, Miyagi Y, Aoki I, Nishioka K, Klinman D, Okuda K. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 164(6):3102-11, 2000.
  222. Hasegawa S, Yang M, Chishima T, Miyagi Y, Shimada H, Moossa AR, Hoffman RM. In vivo tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis. Cancer Gene Ther 7(10):1336-40, 2000.
  223. Nakatani Y, Nakamura N, Sano J, Inayama Y, Kawano N, Yamanaka S, Miyagi Y, Nagashima Y, Ohbayashi C, Mizushima M, Manabe T, Kuroda M, Yokoi T, Matsubara O. Interstitial pneumonia in Hermansky-Pudlak syndrome: significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch 437(3):304-13, 2000.

 

特許等

  1. 発明の名称:PRDM14発現を確認する方法
    出願番号:特願2017-185200
    出願日:2017年9月26日
    発明者:
    地独県立病院機構神奈川県立がんセンター:宮城 洋平
    東京大学医科学研究所:今井 浩三、谷口 博昭、斎藤 杏里
    国立がん研究センター研究所:前沸 均
  2. 発明の名称:がんリスク評価法及びがんリスク評価システム
    出願番号:特願2017-186273
    出願日:2017年9月26日
    発明者:
    地独県立病院機構神奈川県立がんセンター:宮城 洋平
    株式会社レナテック:稲垣 精一、岡本 直幸
    千葉県がんセンター研究所:三上 春夫

スタッフ紹介

　

※メールアドレスの[at]は＠に直してご送信ください。

  • 宮城 洋平みやぎ ようへい

    役職 部長
    Eメール miyagi.0e82r[at]kanagawa-pho.jp
    専門 分子腫瘍学、腫瘍病理学

  • 小井詰 史朗こいづめ しろう

    役職 主任研究員
    Eメール koizume.2230b[at]kanagawa-pho.jp
    専門 分子生物学、分子腫瘍学

  • 佐藤 慎哉さとう しんや

    役職 室長
    Eメール sato.0f80j[at]kanagawa-pho.jp
    専門 病理学、分子生物学、腫瘍学（がん転移）、EV

  • 笠島 理加かさじま りか

    役職 主任研究員（がんゲノム診療センター）
    Eメール kasajima.4080j[at]kanagawa-pho.jp
    専門 がんゲノム解析、分子腫瘍学

  • 項 慧慧Xiang Huihui

    役職 任期付研究員
    Eメール shan.5430k[at]kanagawa-pho.jp
    専門 分子腫瘍学, 腫瘍免疫学

  • 中村 圭靖なかむら よしやす

    役職 専門検査技師
    Eメール nakamura.0c52e[at]kanagawa-pho.jp

  • 高橋 朋子たかはし ともこ

    役職 研究補助員
    Eメール takahashi.3l90d[at]kanagawa-pho.jp

  • 小森 由香子こもり ゆかこ

    役職 研究補助員
    Eメール komori.2v20e[at]kanagawa-pho.jp

  • 大類 久美子おおるい くみこ

    役職 研究補助員
    Eメール oorui.4x40b[at]kanagawa-pho.jp

  • 中川 仁美なかがわ ひとみ

    役職 研究補助員
    Eメール nakagawa.hy20n@kanagawa-pho.jp

  • 吉原 光代よしはら みつよ

    役職 研究補助員
    Eメール yoshihara.4o90j[at]kanagawa-pho.jp

  • 依田 和美よだ かずみ

    役職 事務補助員
    Eメール yoda.5180b[at]kanagawa-pho.jp

  • 竹中 克也たけなか かつや

    役職 受入研究員 （新日本科学TRカンパニー）

  • 宮崎 香みやざき かおる

    役職 客員研究員（横浜市立大学名誉教授）

  • 川本 進かわもと すすむ

    役職 客員研究員（千葉大学 名誉教授）

  • 増永 敦子ますなが あつこ

    役職 客員研究員（昭和大学横浜市北部病院呼吸器外科客員教授）

  • 田所 弘子たどころ ひろこ

    役職 客員研究員 （東京薬科大学薬学部）

  • 谷岡 沙紀たにおか さき

    役職 研究生（横浜市立大学大学院医学研究科）

  • 魚本 真理うおもと まり

    役職 研究生（横浜市立大学大学院医学研究科）

  • 岩泉 しず葉いわいずみ　しずは

    役職 研究生（横浜市立大学大学院医学研究科）

Contact

045-520-2222（代表）

受付時間 9:00～17:00（平日のみ）

お問い合わせ